[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 643
1. Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Santi M, Judkins AR, Rushing EJ: Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases. Ann Diagn Pathol; 2010 Feb;14(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases.
  • Mesenchymal chondrosarcoma is a rare malignant tumor in the differential diagnosis of other small, round blue cell tumors, including atypical teratoid tumor in the central nervous system (CNS) and rhabdomyosarcoma in the musculoskeletal (MSK) locations.
  • We reviewed the morphology of CNS and MSK cases and applied a panel of immunostains.
  • Twenty-two cases included 5 CNS (all female; mean age, 30.2) and 17 MSK (11 female and 6 male; mean age, 31.1).
  • Both CNS and MSK examples had similar round cells, staghorn vascular pattern, increased mitotic activity, and centrally located hyaline cartilage islands.
  • The CNS examples demonstrated more spindling and the MSK cases more necrosis.
  • INI1 was retained in all tumors studied.
  • The CNS and MSK mesenchymal chondrosarcoma predominantly affects adult females with poor prognosis.
  • There are only subtle morphologic differences between the CNS and MSK groups.
  • Retained INI1 separates these tumors from atypical teratoid tumor.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Desmin / metabolism. Mucin-1 / metabolism. Nervous System Neoplasms / pathology. Receptors, Estrogen / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Child. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123451.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Desmin; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


2. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK: Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer; 2009 Mar;16(1):267-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
  • The homeodomain transcription factor NKX2.2 is necessary for neuroendocrine (NE) differentiation in the central nervous system and pancreas.
  • NE tumors derived from the gut are defined by their NE phenotype, which is used for diagnosis and contributes to tumorigenicity.
  • NKX2.2 and NE marker expression was investigated in the small intestine of embryonic and adult mice using immunofluorescence (IF).
  • NKX2.2 and NE marker expression in human NE tumors of the gut and normal tissues were evaluated by immunohistochemistry and qRT-PCR.
  • NKX2.2 expression was detected in the intervillus/crypt regions of embryonic and adult mouse intestine.
  • Co-expression of Nkx2.2 with neurogenin3 (NEUROG3) and hormones was observed in the adult intestinal crypt compartment, suggesting NKX2.2 functions in NEUROG3-positive endocrine progenitors and newly differentiated endocrine cells.
  • NKX2.2 was expressed in most (24 of 29) human NE tumors derived from diverse primary sites.
  • We conclude NKX2.2 functions in immature endocrine cells to control NE differentiation in normal intestine and is expressed in most NE tumors of the gut, and is therefore a novel target of diagnosis for patients with gastrointestinal NE tumors.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Neuroendocrine Tumors / genetics. Transcription Factors / genetics. Transcription Factors / metabolism


3. de Divitiis E, Cavallo LM, Cappabianca P, Esposito F: Extended endoscopic endonasal transsphenoidal approach for the removal of suprasellar tumors: Part 2. Neurosurgery; 2007 Jan;60(1):46-58; discussion 58-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended endoscopic endonasal transsphenoidal approach for the removal of suprasellar tumors: Part 2.
  • RESULTS: Tumor removal, as assessed by postoperative magnetic resonance imaging, revealed complete removal of the lesion in four out of seven pituitary adenomas, five out of seven craniopharyngiomas, three out of three Rathke's cleft cysts, and two out of two tuberculum sellae meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Nasal Cavity / surgery. Neuroendoscopy / methods. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Aged. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / radiography. Central Nervous System Neoplasms / surgery. Female. Humans. Male. Middle Aged. Sphenoid Bone / radiography. Sphenoid Bone / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228252.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Pećina-Slaus N, Niku Eva-Martić T, Beros V, Tomas D: Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases. Pathol Oncol Res; 2007;13(4):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases.
  • The genetic basis as well as mechanisms of development of germ cell tumors of the CNS are still unexplained.
  • In the present article changes of Ecadherin (CDH1) and beta-catenin (CTNNB1) genes in two CNS germ cell tumors are reported.
  • A case of germinoma of the central nervous system and a case of spinal channel teratoma were tested for loss of heterozygosity (LOH) of E-cadherin gene by PCR amplification of tetranucleotide polymorphism (D16S752).
  • Both germ cell tumors analyzed demonstrated LOH of the CDH1 gene.
  • Our findings may contribute to better understanding of the genetic profile of germ cell tumors.
  • [MeSH-major] Cadherins / genetics. Central Nervous System Neoplasms / genetics. Germinoma / genetics. Teratoma / genetics. beta Catenin / genetics
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Female. Humans. Loss of Heterozygosity. Male. Mutation. Pineal Gland / pathology. Pinealoma / genetics. Pinealoma / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1992 Feb;116(4):989-96 [1734027.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):198-201 [12209999.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Acta Neuropathol. 2006 Jun;111(6):563-8 [16718353.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1370-5 [16251967.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Pathol. 2004 Oct;204(2):167-74 [15378486.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23 (31):7951-7 [16258095.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1169-77 [14528308.001]
  • [Cites] J Cutan Pathol. 2007 Mar;34(3):239-46 [17302608.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):569-74 [17083471.001]
  • [Cites] Cancer Cell Int. 2003 Oct 14;3(1):17 [14613514.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24735-8 [9312064.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):392-9 [10851180.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):134-46 [10337997.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):139-51 [11550309.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12 ):1613-8 [17122519.001]
  • [Cites] Pediatr Dev Pathol. 2006 Mar-Apr;9(2):115-31 [16822086.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):445-9 [11433413.001]
  • [Cites] Int J Androl. 2006 Feb;29(1):219-27 [16466543.001]
  • [Cites] Neurosurg Rev. 2003 May;26(2):113-6 [12962297.001]
  • (PMID = 18158575.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


5. Sarin S, Bernath A: Turcot syndrome (glioma polyposis): a case report. South Med J; 2008 Dec;101(12):1273-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Turcot's syndrome (glioma-polyposis) is a rare hereditary disorder characterized by association of colonic polyposis with primary tumors of the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli / pathology. Cerebellar Neoplasms / pathology. Colonic Neoplasms / pathology. Medulloblastoma / pathology. Neoplastic Syndromes, Hereditary / pathology
  • [MeSH-minor] Adult. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. Diagnosis, Differential. Genetic Testing. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Multiple Organ Failure / genetics. Multiple Organ Failure / pathology

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Turcot syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19005436.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M: CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
  • PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.
  • METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
  • The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.
  • No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
  • Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.
  • Relationship between tumor size and site and HCG level should be investigated further.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936563.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


7. Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR: Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res; 2010 Jan 15;16(2):743-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
  • We sought to determine the dose of oral 6-(4-bromo-2-thienyl) methoxy purin-2-amine (lomeguatrib), a pseudosubstrate inactivator of MGMT, required to render active protein undetectable 12 hours after dosing in prostate, primary central nervous system (CNS), and colorectal cancer patients.
  • EXPERIMENTAL DESIGN: Lomeguatrib was administered orally as a single dose (20-160 mg) approximately 12 hours before tumor resection.
  • Dose escalation was projected to continue until grade 2 toxicity or until complete inactivation of tumor MGMT was encountered.
  • RESULTS: Thirty-seven patients were dosed with lomeguatrib, and 32 informative tumor samples were obtained.
  • Mean total MGMT level varied between tumor types: 554 +/- 404 fmol/mg protein (+/-SD) for prostate cancer, 87.4 +/- 40.3 fmol/mg protein for CNS tumors, and 244 +/- 181 fmol/mg protein for colorectal cancer.
  • Complete consistent inactivation in CNS tumors was observed only at the highest dose of lomeguatrib (160 mg).
  • CONCLUSIONS: Total MGMT inactivation can be achieved in prostate, primary CNS, and colorectal cancers with a single administration of 120 or 160 mg lomeguatrib.
  • [MeSH-major] Gene Silencing / drug effects. Neoplasms / drug therapy. Neoplasms / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics. Purines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Biomarkers, Pharmacological / analysis. Combined Modality Therapy. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):248-52 [10629085.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1250-6 [19367283.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):615-7 [12124813.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):37-44 [12517538.001]
  • [Cites] Mini Rev Med Chem. 2003 Aug;3(5):471-85 [12769698.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):165-75 [2233798.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1503-7 [1394831.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2402-10 [10344750.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1152-6 [16278661.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1577-84 [16533784.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2540-5 [17577032.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1614-8 [18475294.001]
  • [Cites] Methods Mol Biol. 2000;152:49-61 [10957968.001]
  • (PMID = 20068091.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6293; United Kingdom / Medical Research Council / / G0900871; United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Pharmacological; 0 / Purines; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; S79265T71M / lomeguatrib
  • [Other-IDs] NLM/ PMC2807621; NLM/ UKMS28074
  •  go-up   go-down


8. Costantini M, Beccaro M, Higginson IJ: Cancer trajectories at the end of life: is there an effect of age and gender? BMC Cancer; 2008;8:127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern was consistent across sub-groups, except for patients affected by Central Nervous System tumors who experienced a longer, slower functional decline.
  • [MeSH-major] Neoplasms / physiopathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Caregivers. Female. Frail Elderly. Humans. Male. Middle Aged. Probability. Quality of Life. Retrospective Studies. Sex Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Palliat Med. 2001 Winter;4(4):457-64 [11798477.001]
  • [Cites] Soc Sci Med. 2003 Jan;56(1):95-109 [12435554.001]
  • [Cites] JAMA. 2003 May 14;289(18):2387-92 [12746362.001]
  • [Cites] J Epidemiol Community Health. 1998 Dec;52(12):802-7 [10396521.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1539-47 [17660496.001]
  • [Cites] Palliat Med. 2005 Dec;19(8):628-38 [16450880.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1037-8 [16766590.001]
  • [Cites] Eur J Public Health. 2007 Jun;17(3):285-90 [17068001.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):971-6 [17043092.001]
  • [Cites] Clin Geriatr Med. 2005 Feb;21(1):45-55, viii [15639036.001]
  • (PMID = 18454854.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2386793
  •  go-up   go-down


9. Salvati M, Caroli E, Frati A, Piccirilli M, Agrillo A, Brogna C, Occhiogrosso G, Giangaspero F: Central nervous system mesenchymal chondrosarcoma. J Exp Clin Cancer Res; 2005 Jun;24(2):317-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system mesenchymal chondrosarcoma.
  • Central nervous system mesenchymal chondrosarcomas are rare malignant tumors that constitute a separate entity from the classical chondrosarcoma and myxoid variant.
  • Clinical behaviour of central nervous system chondrosarcomas is still unknown.
  • We describe two rare examples of intracranial mesenchymal chondrosarcoma with a review of the literature, in an attempt to clarify the clinical characteristics, prognosis and treatment of choice of these unusual tumors.
  • Although clinical behaviour of central nervous system chondrosarcomas remains to be defined, data from our series as well as literature show that radical removal is the best therapeutic choice.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chondrosarcoma, Mesenchymal / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents. Cartilage / pathology. Cell Differentiation. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110767.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Kassam AB, Engh JA, Mintz AH, Prevedello DM: Completely endoscopic resection of intraparenchymal brain tumors. J Neurosurg; 2009 Jan;110(1):116-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completely endoscopic resection of intraparenchymal brain tumors.
  • OBJECT: The authors introduce a novel technique of intraparenchymal brain tumor resection using a rod lens endoscope and parallel instrumentation via a transparent conduit.
  • Postoperative MR imaging or CT was performed to assess for residual tumor in all patients, and all patients were followed up postoperatively to assess for new neurological deficits or other surgical complications.
  • [MeSH-major] Brain Neoplasms / surgery. Endoscopes. Endoscopy / methods. Minimally Invasive Surgical Procedures / instrumentation. Minimally Invasive Surgical Procedures / methods. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Central Nervous System Vascular Malformations / surgery. Female. Follow-Up Studies. Glioblastoma / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / epidemiology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Feb;112(2):473-4 [20121379.001]
  • (PMID = 18950265.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tabaee A, Anand VK, Brown SM, Lin JW, Schwartz TH: Algorithm for reconstruction after endoscopic pituitary and skull base surgery. Laryngoscope; 2007 Jul;117(7):1133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN AND METHODS: Patients undergoing endoscopic skull base surgery underwent an algorithmic approach to reconstruction based on tumor location, defect size, and presence of intraoperative cerebrospinal fluid (CSF) leak.
  • RESULTS: The diagnosis in the 127 patients in this series included pituitary tumor in 70 (55%) patients, encephalocele in 16 (12.6%) patients, meningioma in 11 (8.7%) patients, craniopharyngioma in 9 (7.1%) patients, and chordoma in 6 (4.7%) patients.
  • Correlation between postoperative CSF leak and study variables revealed a statistically significant longer duration of surgery (243 vs. 178 min, P = .008) and hospitalization (12.1 vs. 4.5 days, P < .0001) and a trend toward larger tumors (mean, 3.2 vs. 2.3 cm; P = .058) in patients experiencing postoperative CSF leak.
  • [MeSH-major] Adenoma / surgery. Algorithms. Central Nervous System Cysts / surgery. Endoscopy / methods. Meningeal Neoplasms / surgery. Pituitary Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cerebrospinal Fluid Rhinorrhea / etiology. Encephalocele / etiology. Female. Humans. Male. Middle Aged. Postoperative Complications. Prospective Studies. Risk Factors


12. Logigan C, Mihalache D, Dorneanu O, Turcu T: [Study of nosocomial bacillary meningitis admitted in the Clinic of Infectious Diseases Iaşi on a 20 years period]. Rev Med Chir Soc Med Nat Iasi; 2009 Jul-Sep;113(3):721-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The development of nosocomial meningitis was subsequent to interventions on the central nervous system for hematoma, ventriculo-peritoneal shunts, tumors, rah anesthesia.
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Ceftazidime / therapeutic use. Child. Child, Preschool. Colistin / therapeutic use. Drug Therapy, Combination. Gram-Negative Bacteria / drug effects. Gram-Negative Bacteria / isolation & purification. Hospitals, Isolation. Hospitals, University. Humans. Infant. Infant, Newborn. Medical Records. Middle Aged. Nervous System Diseases / surgery. Quinolones / therapeutic use. Retrospective Studies. Romania. Treatment Outcome

  • Hazardous Substances Data Bank. COLISTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191822.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Quinolones; 9M416Z9QNR / Ceftazidime; Z67X93HJG1 / Colistin
  •  go-up   go-down


13. Subramanian A, Shankar Joshi B, Roy AD, Roy R, Gupta V, Dang RS: NMR spectroscopic identification of cholesterol esters, plasmalogen and phenolic glycolipids as fingerprint markers of human intracranial tuberculomas. NMR Biomed; 2008 Mar;21(3):272-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, phenolic glycolipids present in intracranial tuberculomas may have diagnostic significance in differentiating them from other disease conditions of the central nervous system such as malignant tumors.
  • [MeSH-major] Biomarkers / analysis. Brain Neoplasms / metabolism. Cholesterol Esters / analysis. Glycolipids / analysis. Plasmalogens / analysis. Tuberculoma, Intracranial / metabolism. Tuberculoma, Intracranial / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Spectroscopy. Middle Aged. Phenols / analysis. Tissue Extracts / chemistry

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 John Wiley & Sons, Ltd.
  • (PMID = 17614100.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cholesterol Esters; 0 / Glycolipids; 0 / Phenols; 0 / Plasmalogens; 0 / Tissue Extracts
  •  go-up   go-down


14. Kim EY, Kim SS: Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients. Acta Radiol; 2005 Apr;46(2):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients.
  • PURPOSE: To describe the MR findings of primary central nervous system T-cell lymphoma (T-PCNSL) in immunocompetent patients.
  • The number, location, shape, enhancement pattern, and signal intensity of the tumors were determined.
  • All tumors showed iso- to low T1 and iso- to slightly high T2 signal intensity to the adjacent gray matter.
  • The lower rCBV ratio of the tumor might be helpful in differentiating T-PCNSL from other brain tumors such as high-grade glioma.
  • [MeSH-major] Brain Neoplasms / pathology. Immunocompetence. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebrovascular Circulation / physiology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902895.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med; 2009 Feb 19;360(8):765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas).
  • METHODS: We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors.
  • Tumors without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene.
  • Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes.

  • Genetics Home Reference. consumer health - IDH1 gene.
  • Genetics Home Reference. consumer health - IDH2 gene.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827855335 for PMID:19228619 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Free Radic Res. 2008 Jul;42(7):618-24 [18608518.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249 [19469031.001]
  • [CommentIn] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • (PMID = 19228619.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / 2P30-CA-14236; United States / NCI NIH HHS / CA / 5P50-CA-108786; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / CA062924-150012; United States / NCI NIH HHS / CA / R37 CA043460-26; United States / NCI NIH HHS / CA / 5R37-CA-11898; United States / NCI NIH HHS / CA / R37CA11898-34; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043460-26; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NINDS NIH HHS / NS / NS20023-21; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / P50 CA062924-150012; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA118822; United States / NINDS NIH HHS / NS / 5P50-NS-20023; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human
  • [Other-IDs] NLM/ NIHMS107443; NLM/ PMC2820383
  •  go-up   go-down


16. Lonser RR, Vortmeyer AO, Butman JA, Glasker S, Finn MA, Ammerman JM, Merrill MJ, Edwards NA, Zhuang Z, Oldfield EH: Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol; 2005 Sep;58(3):392-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema is a precursor to central nervous system peritumoral cyst formation.
  • Despite the common occurrence and frequent clinical effects of peritumoral cysts in the central nervous system (CNS), the mechanism underlying their development and evolution is not understood.
  • Because they commonly produce peritumoral cysts and because serial magnetic resonance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas provide an opportunity to examine the pathophysiology of CNS peritumoral cyst formation.
  • Serial MRI was correlated with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangioblastomas (11 spinal cord; 11 cerebellar) that were associated with the appearance and evolution of peritumoral cysts.
  • MRI clearly showed peritumoral edema that developed and slowly and progressively evolved into enlarging hemangioblastoma-associated cysts in all tumors (mean follow-up, 130 +/- 38 months; mean +/- standard deviation).
  • CNS peritumoral cyst formation is initiated by increased tumor vascular permeability, increased interstitial pressure in the tumor, and plasma extravasation with convective distribution into the surrounding tissue.
  • When the delivery of plasma from the tumor exceeds the capacity of the surrounding tissue to absorb the extravasated fluid, edema (with its associated increased interstitial pressure) and subsequent cyst formation occur.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Cysts / pathology. Edema / pathology
  • [MeSH-minor] Adult. Autopsy / methods. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Time Factors. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / cerebrospinal fluid

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Edema.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130092.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


17. Fujisawa H, Hasegawa M, Ueno M: Clinical features and management of five patients with supratentorial subependymoma. J Clin Neurosci; 2010 Feb;17(2):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymoma is a rare low-grade glioma of the central nervous system that is often asymptomatic and discovered incidentally.
  • All tumors developed supratentorially around the foramen of Monro, and their diameters ranged from 18 mm to 90 mm.
  • Of the three symptomatic patients, one presented with sudden loss of consciousness despite having only a small tumor, while in contrast, another patient showed only gradual memory disturbance despite having a very large tumor (90 mm diameter).
  • We concluded that as surgery is the only curative treatment for subependymoma, and even a small tumor can present with sudden deterioration, we recommend early and total resection.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricles / pathology. Glioma, Subependymal / diagnosis. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Asian Continental Ancestry Group. Cerebral Ventriculography. Consciousness Disorders / etiology. Female. Humans. Hydrocephalus / diagnosis. Hydrocephalus / etiology. Hydrocephalus / surgery. Japan. Magnetic Resonance Imaging. Male. Memory Disorders / etiology. Middle Aged. Neurosurgical Procedures. Retrospective Studies. Sex Distribution. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20036555.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


18. Tumialán LM, Brat DJ, Fountain AJ, Barrow DL: An astroblastoma mimicking a cavernous malformation: case report. Neurosurgery; 2007 Mar;60(3):E569-70; discussion E570
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Astroblastomas are rare glial neoplasms that usually occur in young adults and have a predilection for the cerebral hemispheres.
  • Imaging studies reveal circumscribed, contrast-enhancing tumors that contain both cystic and solid components with variable peritumoral edema.
  • Hemorrhage, which suggested the presence of a vascular lesion in this patient, has not been previously described as a feature of this neoplasm.
  • The clinical, radiographic, and pathological features of astroblastomas, as well as the natural history of these rare glial neoplasms, are reviewed.
  • This case illustrates the capacity of astroblastomas to hemorrhage, disguising the classic radiographic findings typical of this glial neoplasm.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / radiography. Hematoma, Epidural, Cranial / radiography. Hematoma, Epidural, Cranial / surgery. Neoplasms, Neuroepithelial / radiography. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Astroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327764.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jinhu Y, Jianping D, Xin L, Yuanli Z: Dynamic enhancement features of cavernous sinus cavernous hemangiomas on conventional contrast-enhanced MR imaging. AJNR Am J Neuroradiol; 2008 Mar;29(3):577-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Progressive contrast "filling in" in the tumors on conventional contrast-enhanced MR images can aid in differentiating between cavernous sinus lesions and suggest the diagnosis of cavernous hemangiomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cavernous Sinus / pathology. Gadolinium DTPA. Hemangioma, Cavernous, Central Nervous System / pathology. Image Enhancement / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Contrast Media. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2009 Jan;30(1):E7 [18945791.001]
  • (PMID = 18065511.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


20. Casella C, Garrone E, Gennaro V, Orengo MA, Puppo A, Stagnaro E, Viarengo P, Vercelli M: [Health conditions of the general population living near a steel plant]. Epidemiol Prev; 2005 Sep-Dec;29(5-6 Suppl):77-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Three epidemiological investigations were performed: on all mortality causes; on tumors incidence; on hospitalizations for respiratory diseases.
  • The studies are based on the Regional Mortality Registry, the Ligurian Tumor Registry and the regional hospital discharge records.
  • RESULTS: In Cornigliano the total mortality is statistically higher among males (SMR 123; n. 1684) and females (SMR 148; n. 2160); in particular all tumours, prostate, brain and emolymphopoietic system were significantly higher among males, while colon-rectum and NOS intestine tumours were higher among females.
  • SMRs were statistically higher in both genders for degenerative illnesses of the nervous central system, brain circulatory disorders and liver cirrhosis; only in males for respiratory tract illnesses and in females for myocardial heart attacks.
  • The incidence has increased to a statistically significant extent among males for all cancer sites (SIR 110; n. 821), and for larynx, brain and emolymphopoietic system tumours.
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Child. Female. Humans. Italy. Male. Middle Aged. Mortality / trends. Neoplasms / mortality. Steel

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16646268.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 12597-69-2 / Steel
  •  go-up   go-down


21. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • In Western blot, anti-IDH1R132H mouse monoclonal antibody mIDH1R132H detected a specific band only in mutated tumors.
  • Immunohistochemistry of 345 primary brain tumors demonstrated a strong cytoplasmic and weaker nuclear staining in 122 cases.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


22. Tandon N, O'Neill TJ, Vollmer DG, Wang M: Intraventricular occurrence of a melanocytoma. J Neurosurg; 2008 Sep;109(3):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanocytomas are rare tumors of the central nervous system that are believed to arise from leptomeningeal melanocytes.
  • Microsurgical resection of a black-colored vascular tumor supplied by the anterior choroidal artery was performed.
  • The patient made an excellent recovery; follow-up imaging revealed no recurrent or residual tumor.
  • The intraventricular occurrence of this tumor suggests that melanocytes may migrate into the choroidal fissure and may infrequently undergo neoplastic proliferation in that location.
  • This case contains implications for the differential diagnosis of intraventricular tumors.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Lateral Ventricles. Melanoma / diagnosis. Melanoma / surgery
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759580.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol; 2006 Apr;36(4):231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
  • OBJECTIVE: We conducted a phase I study to investigate the safety of a weekly WT1 tumor vaccine therapy in patients with solid tumors that had been refractory to all other anti-cancer therapies.
  • Moreover, we performed an exploratory assessment of the anti-tumor effects of WT1 treatment.
  • CONCLUSION: This paper confirms that the potential toxicities of the treatment schedule of weekly WT1 vaccination are acceptable and suggested a potential anti-tumor effect.
  • [MeSH-major] Breast Neoplasms / therapy. Cancer Vaccines / therapeutic use. Central Nervous System Neoplasms / therapy. Glioblastoma / therapy. Immunotherapy. WT1 Proteins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bayes Theorem. Female. Humans. Injections, Intradermal. Male. Middle Aged. Vaccination

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16611662.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / WT1 Proteins
  •  go-up   go-down


24. Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, Mitsui T, Kaneko M, Hatae Y, Hayashi Y, Mabuchi O, Adachi N, Morikawa Y, Nishimura S, Kumagai M, Takamatsu H, Sawada T, Sugimoto T: A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol; 2007 Apr;12(2):137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Patients in the lower-risk groups with embryonal-type tumors had poorer outcomes in this retrospective study.
  • (1) a standard therapy, (2) a rapid central pathology review including a chimera gene analysis for the lower-risk group, and (3) evaluation of the efficacy of the high-dose regimen for the high-risk group in Japan.
  • [MeSH-minor] Adolescent. Adult. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Humans. Infant. Japan / epidemiology. Male. Neoplasm Staging. Orbital Neoplasms / drug therapy. Orbital Neoplasms / mortality. Retrospective Studies. Risk Factors. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / mortality. Surveys and Questionnaires. Survival Rate. Time Factors. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Clin Biol Res. 1994;385:371-5 [7972233.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(1):7-12 [9678789.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Jpn J Surg. 1990 Sep;20(5):503-9 [2243442.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):46-54 [3543238.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Apr-May;20(3):201-10 [12637216.001]
  • (PMID = 17443282.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Elli L, Buscarini E, Portugalli V, Reduzzi L, Reduzzi C, Brambilla G, Menozzi F, Bardella MT, Piodi LP, Caldato M, Zambelli A: Pancreatic involvement in von Hippel-Lindau disease: report of two cases and review of the literature. Am J Gastroenterol; 2006 Nov;101(11):2655-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Von Hippel-Lindau (VHL) disease is an autosomal dominant multicancer syndrome caused by the germline mutation of a tumor suppressor gene.
  • Affected individuals develop benign and malignant tumors of the central nervous system, kidneys, adrenal glands, pancreas, and reproductive system.
  • Although VHL disease is mainly diagnosed after the detection of central nervous system tumors, they may not always be the first presentation.
  • Family screening also revealed the genetic mutation in the patient's son and imaging investigations showed the presence of multiple tumors.
  • [MeSH-minor] Adult. Endosonography. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952288.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


26. Eap C, Litré CF, Noudel R, Theret E, Duntze J, Collin P, Rousseaux P: [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study]. Neurochirurgie; 2010 Oct;56(5):404-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study].
  • [Transliterated title] Tumeur rhabdoïde du système nerveux central chez une adolescente de 16ans : à propos d'un cas.
  • Primitive malignant rhabdoid tumors of the central nervous system are rare and have a poor prognosis.
  • Adult and adolescent cases are exceptional.
  • We report the case of a 16-year-old girl who presented an intratumoral hemorrhage in a rhabdoid tumor.
  • We discuss the different therapeutic options for this patient and review the literature on this kind of tumor.
  • [MeSH-major] Brain Neoplasms. Rhabdoid Tumor

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20594960.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Horie N, Morikawa M, Kitigawa N, Tsutsumi K, Kaminogo M, Nagata I: 2D Thick-section MR digital subtraction angiography for the assessment of dural arteriovenous fistulas. AJNR Am J Neuroradiol; 2006 Feb;27(2):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Although dynamic contrast-enhanced MR angiography studies for arteriovenous malformations (AVFs) and brain tumors have shown promising results, no formal attempt has yet been made to similarly evaluate dural AVFs.
  • [MeSH-major] Angiography, Digital Subtraction / methods. Central Nervous System Vascular Malformations / diagnosis. Image Processing, Computer-Assisted / methods. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Embolization, Therapeutic. Female. Follow-Up Studies. Hemodynamics / physiology. Humans. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484389.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Iglesias-Rozas JR, Hopf N: Histological heterogeneity of human glioblastomas investigated with an unsupervised neural network (SOM). Histol Histopathol; 2005 04;20(2):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological variability of Glioblastomas (GB) precludes the modern assimilation of theses tumors into a single histological tumor group.
  • In all tumors 50 histological features, as well as the age and sex of the patients, were examined.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Glioblastoma / classification. Glioblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Child. Child, Preschool. Cluster Analysis. Databases, Factual. Female. Humans. Infant. Male. Middle Aged. Neural Networks (Computer)

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736037.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Hu W, Li L, Shi D, Guo F, Wei D, Gu P, Miao Y, Chen G: Radiofrequency thermocoagulation-assisted surgery for intracranial giant vasogenic tumors. Surg Neurol; 2008 Dec;70(6):570-4; discussion 574-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency thermocoagulation-assisted surgery for intracranial giant vasogenic tumors.
  • BACKGROUND: We report the novel use of radiofrequency thermocoagulation to facilitate surgical excision of intracranial giant vasogenic tumors and detail the operative procedures and patient outcomes.
  • MATERIALS AND METHODS: There were 2 patients with intracranial giant vasogenic tumors.
  • The tumors were well exposed during surgery and separated from the surrounding brain tissue by blunt dissection.
  • The external surface of each tumor was devascularized.
  • Radiofrequency thermocoagulation was applied in multiple cycles with each cycle encompassing a 3-cm-diameter volume to coagulate the inner tissue of the tumors prior to resection.
  • The tumors were then resected in a piecemeal fashion starting from the thermocoagulated regions until complete removal was achieved.
  • RESULTS: With radiofrequency thermocoagulation assistance, the 2 intracranial giant vasogenic tumors were removed completely with no bleeding.
  • No complications and no tumor recurrences have occurred over a 2-year follow-up period.
  • CONCLUSIONS: Radiofrequency thermocoagulation is extremely effective in controlling bleeding during surgical excision of intracranial giant vasogenic tumors.
  • This improves the ease and safety of such procedures and allows for complete removal of tumors.
  • [MeSH-major] Brain Neoplasms / surgery. Electrocoagulation / methods. Hemangioma, Cavernous, Central Nervous System / surgery. Hemangiopericytoma / surgery
  • [MeSH-minor] Adult. Aged. Dissection. Female. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514279.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


31. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol; 2007 Jul 20;25(21):3137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
  • PURPOSE: A dose-escalation phase I and pharmacokinetic study of the farnesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors.
  • RESULTS: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years).
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Enzyme Inhibitors / pharmacokinetics. Farnesyltranstransferase / antagonists & inhibitors. Neoplasm Invasiveness / pathology. Piperidines / pharmacokinetics. Pyridines / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Piperidines; 0 / Pyridines; 193275-84-2 / lonafarnib; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


32. Sharma MC, Ghara N, Jain D, Sarkar C, Singh M, Mehta VS: A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology; 2009 Apr;29(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas.
  • Ependymomas are CNS tumors that originate from the spinal canal and walls of the ventricular system.
  • Histopathologic grades show relationship with MIB1 and Topo IIalpha labelling indices and cut-off values of 5% can differentiate between anaplastic and lower grades. p53 and MDM2 proteins expression are not common in ependymomas; however, they are seen in higher grades only and may be involved in the tumor progression.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. DNA Topoisomerases, Type II / metabolism. Ependymoma / metabolism. Ependymoma / pathology. Ki-67 Antigen / metabolism. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721229.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


33. Alston RD, Geraci M, Eden TO, Moran A, Rowan S, Birch JM: Changes in cancer incidence in teenagers and young adults (ages 13 to 24 years) in England 1979-2003. Cancer; 2008 Nov 15;113(10):2807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data on 39,129 neoplasms in individuals ages 13 to 24 years who were diagnosed in England from 1979 to 2003 were analyzed.
  • RESULTS: Incidence rates of leukemias, lymphomas, central nervous system, bone, and germ cell tumors; melanoma; and carcinomas of the thyroid, ovary, cervix, and colon/rectum increased over time (all P < .01); whereas the incidence of carcinomas of the stomach and bladder decreased (both P < .01).
  • These changes were consistent by age, sex, and region for most neoplasms.
  • [MeSH-major] Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Age Distribution. England / epidemiology. Female. Humans. Incidence. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846564.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Kim KE, Kim KU, Kim DC, Park JI, Han JY: Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea. J Korean Med Sci; 2009 Jun;24(3):453-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea.
  • The World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporates morphology, cytogenetics, molecular genetics, and immunologic markers.
  • Despite the relatively large number of CNS tumors with clonal chromosome abnormalities, only few studies have investigated cytogenetic abnormalities for CNS tumors in Korea.
  • Thus, we investigated 119 CNS tumors by conventional G-banded karyotypes to characterize patterns of chromosomal abnormalities involving various CNS tumors, and 92.4% of them were cultured and karyotyped successfully.
  • Totally, 51.8% of karyotypable CNS tumors showed abnormal cytogenetic results, including neuroepithelial tumors (75.0%), meningeal tumors (71.1%), pituitary adenomas (4.2%), schwannomas (44.4%), and metastatic tumors (100.0%).
  • Abnormal karyotypes were more complex at high-grade tumors, suggesting that the karyotype reflects the biologic nature of the tumor.
  • More detailed cytogenetic and molecular characterizations of CNS tumors contribute to better diagnostic criteria and deeper insights of tumorigenesis, eventually resulting in development of novel therapeutic strategies.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Central Nervous System Neoplasms / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glioblastoma / genetics. Humans. Karyotyping. Korea. Male. Meningeal Neoplasms / genetics. Middle Aged. Neurilemmoma / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):95-101 [11083072.001]
  • [Cites] Expert Rev Neurother. 2004 Jul;4(4):649-63 [15853584.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):85-96 [8527398.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Sep;90(2):109-17 [8830718.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):1-8 [9140447.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] J Pathol. 1999 Aug;188(4):395-9 [10440750.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • (PMID = 19543509.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698192
  • [Keywords] NOTNLM ; Central Nervous System Neoplasms / Chromosome Abnormality / Karyotype / Solid Tumor / WHO Classification
  •  go-up   go-down


35. Chuang MT, Lin WC, Tsai HY, Liu GC, Hu SW, Chiang IC: 3-T proton magnetic resonance spectroscopy of central neurocytoma: 3 case reports and review of the literature. J Comput Assist Tomogr; 2005 Sep-Oct;29(5):683-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3-T proton magnetic resonance spectroscopy of central neurocytoma: 3 case reports and review of the literature.
  • Central neurocytoma (CNC), first described by Hassoun et al in 1982, is a rare neuronal tumor of the central nervous system, accounting for 0.25% to 0.5% of all central nervous system tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy. Neurocytoma / diagnosis. Neurocytoma / metabolism
  • [MeSH-minor] Adult. Alanine / metabolism. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Creatine / metabolism. Female. Glycine / metabolism. Humans. Male

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163043.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  • [Number-of-references] 13
  •  go-up   go-down


36. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


37. Han SR, Sohn MJ, Yoon SW, Yee GT, Choi CY, Lee DJ, Whang CJ: Extracranial metastases of a supratentorial primitive neuroectodermal tumour. J Clin Neurosci; 2007 Jan;14(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracranial metastases from primary central nervous system (CNS) tumours have rarely been reported in the literature, and glioblastomas and medulloblastomas constitute the majority of these.
  • The tendency of supratentorial primitive neuroectodermal tumours (PNET) to spread within the CNS is well-known, but few cases of extracranial metastases of supratentorial PNET have been reported.
  • [MeSH-major] Lung Neoplasms / secondary. Neuroectodermal Tumors, Primitive / secondary. Spinal Neoplasms / secondary. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092726.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


38. Hlobilkova A, Ehrmann J, Knizetova P, Krejci V, Kalita O, Kolar Z: Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma; 2009;56(4):284-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytomas, particularly high grade astrocytoma, are brain tumors with potent angiogenic activity.
  • Our immnunohistochemical study assessed vascular endothelial growth factor (VEGF), VEGF receptors (Flk-1, and Flt-1), the intermediate filamental protein nestin which plays a role in central nervous system development, and MMP-9, which belongs the family of matrix metalloproteinases implicated in tumor invasion and angiogenesis regulation.
  • We investigated the expression of VEGF, its receptors, nestin and MMP-9 in astrocytomas and their correlation with tumor grade.
  • Expression of Flt-1 and Flk-1 showed no significant differences between low and high grade tumor groups.
  • Nestin expression in tumor astrocytes and endothelial cells increased in high grade group (p same 0.007 and 0.003).
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Intermediate Filament Proteins / metabolism. Matrix Metalloproteinase 9 / metabolism. Nerve Tissue Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Nestin. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473053.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


39. Schievink WI, Riedinger M, Maya MM: Frequency of incidental intracranial aneurysms in neurofibromatosis type 1. Am J Med Genet A; 2005 Apr 1;134A(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified patients with NF1 who were hospitalized at Cedars-Sinai Medical Center, Los Angeles, California, between January 1, 1997 and December 31, 2001 through the hospital's centralized medical records system using DRG codes.
  • The mean age of the 39 patients was 30.4 years, and 22 patients had undergone MRI of the brain for the evaluation of symptoms due to the presence of central or peripheral nervous system tumors.
  • This was significantly (P < 0.005) higher than the aneurysm detection rate in a control population (0/526 [0%]) of patients hospitalized for primary or secondary brain tumors, all of whom had undergone MRI examination.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Risk Factors


40. Bare JB, Abramowsky CR, Hayes LL, Shehata BM: Congenital immature teratoma of the central nervous system: three case reports with literature review. Fetal Pediatr Pathol; 2007 May-Jun;26(3):109-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital immature teratoma of the central nervous system: three case reports with literature review.
  • All tumors were deemed to be unresectable.
  • Congenital CNS teratoma should be considered in the differential diagnosis of fetuses diagnosed with macrocephaly or hydrocephaly.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Fetal Diseases / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Gestational Age. Humans. Male. Pregnancy. Prenatal Diagnosis. Review Literature as Topic

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886021.001).
  • [ISSN] 1551-3815
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Price S, Harless W, Rikhye S, Altaha R: A fatal outcome in a patient with glioblastoma multiforme after receiving high-dose methotrexate. J Oncol Pharm Pract; 2008 Mar;14(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common adult primary brain tumor is glioblastoma multiforme (GBM).
  • Central nervous system tumors.
  • Intracranial tumors.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Hernia / etiology. Humans. Intracranial Pressure / drug effects. Neurotoxicity Syndromes / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337442.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Cavallaro G, Basile U, Polistena A, Giustini S, Arena R, Scorsi A, Zinnamosca L, Letizia C, Calvieri S, De Toma G: Surgical management of abdominal manifestations of type 1 neurofibromatosis: experience of a single center. Am Surg; 2010 Apr;76(4):389-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mainly involved districts are skin, the central nervous system, and eye and there is a wide range of severity of clinical presentations.
  • Abdominal manifestations of NF1 include five kinds of tumors: neurogenic tumors (neurofibromas, malignant peripheral nerve sheath tumors [MPNSTs], and ganglioneuromas); neuroendocrine tumors (pheochromocytomas and carcinoids); nonneurogenic gastrointestinal stromal tumors (GISTs); embryonal tumors; and miscellaneous.
  • In the group of patients with a diagnosis of von Recklinghausen disease, 10 patients underwent surgical treatment for gastrointestinal and retroperitoneal tumors associated with NF1.
  • Early diagnosis of these abdominal manifestations is very important because of the risk of malignancy, organic complications (such as pheochromocytoma), or hemorrhagic-obstructive complications such as in case of tumors of the gastrointestinal tract (GISTs and neurofibromas).
  • Further studies are necessary to detect predictive factors of malignant tumor development of severe clinical conditions.
  • [MeSH-major] Abdominal Neoplasms / surgery. Neurofibromatosis 1 / surgery
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Adult. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420249.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Rushing EJ, Olsen C, Mena H, Rueda ME, Lee YS, Keating RF, Packer RJ, Santi M: Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg; 2005 Dec;103(6 Suppl):489-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients.
  • OBJECT: The occurrence of meningiomas in children younger than 20 years of age is rare, accounting for less than 3% of all childhood tumors of the central nervous system.
  • Seven patients had undergone radiotherapy for a prior neoplasm.
  • Tumor location was supratentorial in 64% of the patients, infratentorial in 16%, intraventricular in 12%, and spinal in 8%.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology. Meningioma / pathology. Meningioma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Ataxia / etiology. Basal Cell Nevus Syndrome / complications. Child. Child, Preschool. Cohort Studies. Female. Headache / etiology. Humans. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local. Neurofibromatosis 2 / complications. Neurosurgical Procedures. Paresis / etiology. Retrospective Studies. Seizures / etiology. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383246.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kobayashi TK, Bamba M, Ueda M, Nishino T, Muramatsu M, Hino A, Shima A, Echigo T, Oka H: Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases. Acta Cytol; 2010 Mar-Apr;54(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases.
  • BACKGROUND: Central neurocytoma is a rare central nervous system tumor typically found in the lateral ventricles and at the spectrum pellucidum.
  • Two patients with central neurocytoma underwent intraoperative frozen section diagnoses, and the cytologic evaluations are described.
  • Magnetic resonance imaging (MRI) showed enhancement of a ventricular tumor.
  • Over 80% of the tumor was removed, but after 14 months' follow-up, the disease progressed and regrowth occurred.
  • The patient had a second tumor resection with gamma knife surgery.
  • An MRI showed an enhancement of a ventricular tumor, and complete tumor removal was achieved.
  • In both cases histopathologic examination was consistent with a central neurocytoma.
  • Immunohistochemistry of both tumors was synaptophysin(+), NSE (+), NeuN(+), GFAP(-), but MIB-1 labeling index was 3.4% in case 1 and 1.1% in case 2.
  • CONCLUSION: These are 2 illustrative cases in which the authors report cytologic evaluation of central neurocytomna in intraoperative preparations.
  • These tumors possess distinct cellular features that help with the intraoperative distinction from other intraventricular tumors.
  • Moreover, it should be emphasized that immunostains for neural markers are essential for distinguishing them from other clear cell tumors of the brain, especially oligodendroglioma and clear cell ependymomal neoplasm.
  • A combination of imaging, cytomorphology and immunohistochemical features of central neurocytoma can help to differentiate this condition from other intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adult. Antigens, Nuclear / metabolism. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / metabolism. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391982.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nerve Tissue Proteins; 0 / Synaptophysin; 0 / neuronal nuclear antigen NeuN, human; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


45. Saad AG, Sachs J, Turner CD, Proctor M, Marcus KJ, Wang L, Lidov H, Ullrich NJ: Extracranial metastases of glioblastoma in a child: case report and review of the literature. J Pediatr Hematol Oncol; 2007 Mar;29(3):190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma (GBM) is the most common adult malignant brain tumor but is notably less common in children.
  • Primary brain tumors rarely metastasize outside the central nervous system and when metastases occur, it is often in patients with diversionary shunting of the cerebrospinal fluid.
  • At autopsy, the tumor was found to extensively infiltrate the leptomeninges as well as the cranial skin and soft tissue.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Autopsy. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Neoplasm Metastasis. Tomography, X-Ray Computed


46. Hovén E, Anclair M, Samuelsson U, Kogner P, Boman KK: The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol; 2008 Nov;30(11):807-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This category included central nervous system tumors, acute myeloid leukemia, and bone tumors.
  • Heightened vulnerability to distress signals exceptional needs for support and information among parents of children treated for central nervous system or bone tumors.
  • [MeSH-major] Neoplasms / psychology. Parent-Child Relations. Parents / psychology. Stress, Psychological
  • [MeSH-minor] Adolescent. Adult. Anxiety / diagnosis. Anxiety / etiology. Child. Child, Preschool. Cranial Irradiation. Depression / diagnosis. Depression / etiology. Disease Progression. Female. Humans. Infant. Infant, Newborn. Internal-External Control. Male. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989157.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Lee WS, Koh YS, Kim JC, Park CH, Joo YE, Kim HS, Cho CK, Choi SK, Rew JS, Kim SJ: Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report. BMC Cancer; 2005;5:85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder with characteristic features of skin and central nervous system involvement.
  • Zollinger-Ellison syndrome is caused by gastrin-secreting tumors called gastrinomas.
  • [MeSH-minor] Adult. Biopsy. Endoscopy. Female. Gastrinoma / complications. Gastrinoma / diagnosis. Gastrins / biosynthesis. Gastrins / blood. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-kit / biosynthesis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Genetic Alliance. consumer health - Zollinger-Ellison syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Gastroenterol Nutr. 2001 Aug;33(2):149-54 [11568515.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):25-31 [6691547.001]
  • [Cites] J Gastroenterol. 2002;37(3):215-9 [11931536.001]
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • [Cites] Minerva Endocrinol. 2004 Mar;29(1):19-24 [15258554.001]
  • [Cites] Neurology. 1974 Dec;24(12):1144-51 [4374669.001]
  • [Cites] Gastroenterology. 1981 Jun;80(6):1615-6 [6262186.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2206-8 [6406032.001]
  • [Cites] J Clin Gastroenterol. 1984 Dec;6(6):529-34 [6439777.001]
  • [Cites] Gastroenterol Clin Biol. 1985 Jan;9(1):65-9 [3920107.001]
  • [Cites] Science. 1987 May 29;236(4805):1100-2 [3107130.001]
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9658-62 [1946382.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):199-206 [8323088.001]
  • [Cites] Am J Gastroenterol. 1994 Oct;89(10):1888-90 [7942689.001]
  • [Cites] J Clin Gastroenterol. 1994 Oct;19(3):184-8 [7806825.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):67-73 [7745981.001]
  • [Cites] Acta Derm Venereol. 1995 Mar;75(2):136-40 [7604643.001]
  • [Cites] Postgrad Med J. 1995 Aug;71(838):485-6 [7567757.001]
  • [Cites] Neurology. 1996 Jun;46(6):1652-60 [8649565.001]
  • [Cites] Postgrad Med J. 1996 Jan;72(843):59-60 [8746290.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2125-31 [9179058.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neuroradiology. 1997 Sep;39(9):642-53 [9335063.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):477-88 [9681846.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] J Urol. 1999 Nov;162(5):1582-6 [10524872.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1169-74 [11706080.001]
  • (PMID = 16042772.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC1181810
  •  go-up   go-down


48. Zhang R, Zhou LF, Mao Y: [Microsurgical treatment of nonmeningeal tumors of the cavernous sinus]. Zhonghua Yi Xue Za Zhi; 2005 Jun 1;85(20):1373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microsurgical treatment of nonmeningeal tumors of the cavernous sinus].
  • OBJECTIVE: To analyze the differential diagnosis of and effectiveness of surgical treatment on nonmeningeal tumors of cavernous sinus.
  • METHODS: The clinical data, including clinical manifestations, diagnosis and differential diagnosis, operative procedure, and treatment results of 67 cases of nonmeningeal tumors of cavernous sinus, 32 males and 35 females, aged 41 +/- 16, who underwent microsurgical treatment were analyzed respectively.
  • Pathological examination revealed that hemangioma (24 cases), trigeminal schwannoma (18 cases), and invasive pituitary adenomas (11 cases) comprised the majority of tumors; the remaining tumor types were chordoma, chondroma, chondromyosarcoma, chondrofibroma, dermoid tumor, malignant nerve sheath tumor, metastatic tumor, and lymphoma.
  • In the intradural approach group, total tumor removal was achieved in 8 cases (40%), and 7 (35%) cases and 5 (25%) cases had subtotal and partial resection respectively.
  • In the epidural approach group, 27 cases (81.8%) had total tumor removal, while 1 case (3.0%) had subtotal and 5 cases had partial excision of the tumor.
  • Postoperative follow-up lasting 6 months to 10 years showed that the pre-operative central nervous system symptoms recovered in 39 cases (58.2%).
  • CONCLUSION: Depending on pathologic type and growth pattern of the tumor, extended middle skull base epidural or epidural-transdural approach is selected.
  • Such techniques can offer satisfactory outcome, protecting the cranial nerve functions and removing the tumor to the maximum extent.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Cranial Nerve Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Microsurgery. Trigeminal Nerve Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cavernous Sinus / surgery. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurilemmoma / diagnosis. Neurilemmoma / surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029646.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ: Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer; 2010 Apr;54(4):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
  • BACKGROUND: Thiotepa and carboplatin are known to be active in central nervous system tumors.
  • We present ten patients with recurrent or progressive central nervous system malignancies treated on a myeloablative regimen using these drugs.
  • CONCLUSION: Thiotepa/topotecan/carboplatin may help consolidate remission of poor prognosis pediatric central nervous system tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prognosis. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998470.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


50. Sawada T, Kato Y, Kobayashi M: Expression of aquaporine-4 in central nervous system tumors. Brain Tumor Pathol; 2007;24(2):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporine-4 in central nervous system tumors.
  • Cerebral edema is associated with common brain tumors.
  • To elucidate the characterization of the expression of AQP4 and the relationship of the expression of VEGF, we investigated the expression of AQP4 in tumors of the central nervous system immunohistochemically.
  • Brain tumors and nontumorous cerebral tissue for control were evaluated by immunohistochemical staining using anti-AQP4, VEGF, CD34, and MIB-1.
  • In tumor cells, only glial tumor cells showed a positive reaction for AQP4.
  • Although endothelial cells were negative and/or weakly positive for AQP4, the positive relationship suggested the expression of VEGF in endothelial cells in neovasculature and that of AQP 4 in tumor cells.
  • APQ4 expression increased in human astrocytic tumors and edematous cerebral tissue.
  • Upregulation of APQ4 by tumor cells and reactive astroglia were major factors of cerebral edema.
  • [MeSH-major] Aquaporin 4 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Brain Edema / etiology. Brain Edema / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


51. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM, Children's Oncology Group: Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
  • O(6)-benzylguanine (O(6)-BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of BCNU administered following O(6)-BG.
  • Once the MTD was exceeded, Stage II accrual was limited to less heavily pretreated patients (</= two prior chemotherapy regimens, no prior central axis radiation, no prior bone marrow transplant, and no bone marrow involvement).
  • CONCLUSIONS: Based on lack of activity of this combination in adult phase II studies, no further testing of O(6)-BG plus BCNU in children is planned.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / pharmacology. Central Nervous System Neoplasms / drug therapy. Guanine / analogs & derivatives. Neoplasm Proteins / antagonists & inhibitors. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. DNA Repair / drug effects. DNA, Neoplasm / drug effects. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Salvage Therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941066.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 97543; United States / NCRR NIH HHS / RR / M01 RR00188; United States / NCI NIH HHS / CA / U01 CA97552
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


52. Aigner L, Bogdahn U: TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res; 2008 Jan;331(1):225-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta in neural stem cells and in tumors of the central nervous system.
  • Mechanisms that regulate neural stem cell activity in the adult brain are tightly coordinated.
  • Signals provided by proteins of the transforming growth factor (TGF)-beta family might represent a system by which neural stem cells are controlled under physiological conditions but released from this control after transformation to cancer stem cells.
  • It is induced in the adult brain after injury or hypoxia and during neurodegeneration when it modulates and dampens inflammatory responses.
  • Similar to its effect on neural stem cells, TGF-beta reveals anti-proliferative control on most cell types; however, paradoxically, many brain tumors escape from TGF-beta control.
  • Moreover, brain tumors develop mechanisms that change the anti-proliferative influence of TGF-beta into oncogenic cues, mainly by orchestrating a multitude of TGF-beta-mediated effects upon matrix, migration and invasion, angiogenesis, and, most importantly, immune escape mechanisms.
  • Thus, TGF-beta is involved in tumor progression.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Neurons / cytology. Stem Cells / metabolism. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710437.001).
  • [ISSN] 1432-0878
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  • [Number-of-references] 205
  •  go-up   go-down


53. Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW, Hong YK: Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol; 2009 Mar;92(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant.
  • We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy.
  • There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System Neoplasms / metabolism. Lymphoma, Non-Hodgkin / metabolism. Methotrexate / administration & dosage. STAT6 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):556-64 [8636771.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):94-103 [6689733.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):939-47 [2914300.001]
  • [Cites] Cell Res. 2007 Nov;17(11):942-55 [17968425.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):843-7 [15929034.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Mar;57(3):245-53 [16213149.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Neurosci. 1998 Oct;5(4):409-12 [18639063.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2924-32 [15591113.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] Neurology. 1996 Jun;46(6):1757-9 [8649588.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):259-68 [10563432.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1682-8 [15251157.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1550-64 [17705178.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Neurology. 2004 Feb 24;62(4):544-7 [14981168.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):40-4 [11302253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):457-64 [11380234.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):351-6 [15034788.001]
  • [Cites] Radiology. 1990 Sep;176(3):855-60 [2389047.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Onkologie. 2006 Oct;29(10):455-9 [17028454.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6333-41 [16144938.001]
  • (PMID = 19030780.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


54. Tunca B, Bekar A, Cecener G, Egeli U, Vatan O, Tolunay S, Kocaeli H, Aksoy K: Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neurooncol; 2007 May;82(3):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) represents the most common and aggressive type of primary neoplasms of the central nervous system.
  • The PTEN (phosphatase, tensin homologue, deleted on chromosome TEN; MIM # 601728) tumor suppressor gene has an essential biological role in the formation of glioblastomas.
  • It is known that there are variations in genetic alterations in tumors that develop in patients with different ethnic backgrounds and because there is no study evaluating PTEN mutation in Turkish patients with GBM, we aimed to realize the present study.
  • We investigated 62 GBM tumors for mutations of the PTEN gene using single strand conformational polymorphism (SSCP) method followed by DNA sequencing.
  • As a result of our investigation, PTEN mutations were detected in 15 of 62 tumors (24.19%).
  • Furthermore, though no significant correlation was found between PTEN mutations and histopathological properties of GBM tumors, our findings indicate that localizations of mutations in PTEN gene may have an effect on clinical aggressiveness of GBM tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Mutation. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Turkey

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7033-8 [11156408.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3937-43 [11051241.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):89-94 [11083071.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Hum Mol Genet. 2005 Aug 15;14 (16):2459-68 [16014636.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):450-4 [14623110.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7 [10468583.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):12-8 [16410744.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23 ):12479-84 [9356475.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • (PMID = 17151929.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human
  •  go-up   go-down


55. Miyamoto J, Tatsuzawa K, Owada K, Kawabe T, Sasajima H, Mineura K: Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors. Neurol Med Chir (Tokyo); 2008;48(11):495-9; discussion 499
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors.
  • Fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]FDG PET) was assessed as a method for providing information about the malignancy of orbital tumors.
  • Twelve patients with 13 orbital tumors underwent [18F]FDG PET followed by biopsy or tumor removal via a transcranial approach.
  • The accumulation ratio between the tumor and the contralateral normal tissue (T/N ratio) was calculated for 10 of the 13 lesions.
  • The T/N ratio in benign lesions was compared with that in malignant tumors.
  • The T/N ratio was 1.06 +/- 0.03 (mean +/- standard deviation) in benign tumors, and significantly higher at 1.81 +/- 0.27 in malignant tumors (p = 0.0027).
  • [18F]FDG PET can determine the malignancy of orbital tumors, but cannot distinguish malignant tumor from inflammatory disease such as pseudotumor.
  • [MeSH-major] Optic Nerve Neoplasms / radionuclide imaging. Orbital Neoplasms / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adolescent. Adult. Aged. Astrocytoma / radionuclide imaging. Carcinoma, Adenoid Cystic / radionuclide imaging. Diagnosis, Differential. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Glioblastoma / radionuclide imaging. Hemangioma, Cavernous, Central Nervous System / radionuclide imaging. Humans. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Male. Melanoma / radionuclide imaging. Middle Aged. Neurilemmoma / radionuclide imaging. Orbital Pseudotumor / radionuclide imaging. Radiopharmaceuticals. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029776.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. El-Rayes BF, Norton CS, Sakr W, Maciorowski Z, Smith D, Pietraszkiewicz H, Del Mar Alonso M, Ensley JF: Cellular DNA content parameters as prognostic indicators in human astrocytomas. J Neurooncol; 2005 Jan;71(2):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Clinical parameters such as grade, size and/or location of the tumor are good predictors of outcome in patients with astrocytoma.
  • The objective of this study was to determine whether DNA content parameters have a prognostic significance for this group of tumors.
  • METHODS: Following optimization and validation of methodology for evaluating cellular DNA content parameters (CDCP), tumor DNA ploidy and percent S phase fraction (SPF) were determined from 64 patients using formalin fixed, paraffin embedded specimens (mean coefficient of variation=4.94) obtained over a 10-year period.
  • Survival did not correlate with overall differences in DNA ploidy (DNA-D=181 vs. DNA-A=206days, P=0.6314) when treated and untreated tumors were analyzed.
  • However, a trend for prolonged median survival was observed in patients whose tumors were untreated with respect to cytotoxic therapy based on DNA ploidy status (DNA-D=275 vs. DNA-A=15days, P=0.3408).
  • [MeSH-major] Astrocytoma / metabolism. Central Nervous System Neoplasms / metabolism. DNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Antineoplastic Agents / therapeutic use. Diploidy. Female. Flow Cytometry. Humans. Male. Middle Aged. Prognosis. Radiotherapy. S Phase. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Jul 1;60(1):59-65 [2438028.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cytometry. 1985 Jul;6(4):327-33 [4017799.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Neuropathol. 1986 Jul-Aug;5(4):157-75 [3757347.001]
  • [Cites] Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):331-8 [2779735.001]
  • [Cites] J Neurosurg. 1980 Aug;53(2):198-204 [7431058.001]
  • [Cites] Neurosurg Rev. 1988;11(2):177-87 [3244416.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):663-7 [2071227.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):289-93 [2843034.001]
  • [Cites] J Neurosurg. 1994 May;80(5):877-83 [8169628.001]
  • [Cites] Cytometry. 1988 Jul;9(4):380-6 [2841078.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] Pol J Pathol. 1997;48(1):31-6 [9200958.001]
  • [Cites] Cytometry. 1987 Sep;8(5):479-87 [2444398.001]
  • [Cites] Cell Tissue Kinet. 1982 May;15(3):235-49 [7083295.001]
  • [Cites] Folia Histochem Cytobiol. 2000;38(4):175-80 [11185722.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):13-21 [207834.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 May;16(5):1001-12 [7639120.001]
  • [Cites] Acta Neuropathol. 1979 Apr 12;46(1-2):39-44 [222110.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):85-9 [8271026.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):153-8 [9739018.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):77-89 [8055485.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):119-25; discussion 125-6 [7936132.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):920-7 [8039120.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):711-28 [3001488.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):379-84 [2536805.001]
  • [Cites] Cytometry. 1983 Mar;3(5):328-31 [6839881.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):113-7 [8548733.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):7-17 [9049858.001]
  • [Cites] J Neuropathol Exp Neurol. 1990 Jan;49(1):71-8 [2153761.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):37-45 [8865001.001]
  • [Cites] Am J Clin Pathol. 1988 May;89(5):640-4 [2895977.001]
  • [Cites] Cytometry. 1987 Sep;8(5):488-93 [3665673.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):538-46 [1319820.001]
  • (PMID = 15690121.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 40498-01A1; United States / NCI NIH HHS / CA / P30CA22453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm
  •  go-up   go-down


57. Vougiouklakis T, Mitselou A, Agnantis NJ: Sudden death due to primary intracranial neoplasms. A forensic autopsy study. Anticancer Res; 2006 May-Jun;26(3B):2463-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden death due to primary intracranial neoplasms. A forensic autopsy study.
  • Although most fatal tumors are diagnosed well before a patient's death, occasionally forensic pathologists encounter cases in which the presence of a primary tumor of the central nervous system had not been suspected prior to death.
  • A search for cases of sudden death due to intracranial tumors from a total of 1985 autopsies from the archives of the Department of Forensic Pathology, University of Ioannina, Greece, in the period 1998-2005, was undertaken.
  • Two such cases in which a medico-legal autopsy had disclosed brain tumors were found.
  • The second case involved a 67-year-old man presenting with brain tumor, diagnosed 1.5 months previously.
  • In both cases, the tumors may, directly or indirectly, have been the underlying cause of death.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Autopsy. Death, Sudden. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821633.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


58. Abdullah S, Morgensztern D, Rosado MF, Lossos IS: Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature. Leuk Lymphoma; 2005 Nov;46(11):1651-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucosa-associated lymphoid tissue extranodal marginal zone lymphomas are the most common subtype of non-Hodgkin's lymphomas that present as primary cranial dura tumors.
  • Mucosa-associated lymphoid tissue extranodal marginal zone lymphomas are the most common subtype of non-Hodgkin's lymphomas that present as primary cranial dura tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Dura Mater / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Humans. Immunophenotyping. Lymphoma, B-Cell. Magnetic Resonance Imaging. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334908.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Sani S, Smith A, Leppla DC, Ilangovan S, Glick R: Epidermoid cyst of the sphenoid sinus with extension into the sella turcica presenting as pituitary apoplexy: case report. Surg Neurol; 2005 Apr;63(4):394-7; discussion 397
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epidermoids of the central nervous system are rare tumors.
  • [MeSH-minor] Acute Disease. Adult. Diplopia / etiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808736.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, Hampl JA, Heppner FL, Zoubaa S, Holinski-Feder E, Pietsch T, Wiestler OD, von Knebel Doeberitz M, Roth W, Gebert J: Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol; 2007 Apr;17(2):146-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability in pediatric and adult high-grade gliomas.
  • About 15% of sporadic gastrointestinal and endometrial tumors show the microsatellite instability (MSI) phenotype because of loss of DNA mismatch repair (MMR) function.
  • The incidence of MSI in tumors of the central nervous system still remains controversial.
  • Based on these data and the fact that in different tumor entities MMR deficiency defines a subgroup of tumors with distinct pathogenesis and particular clinicopathological features that may have impact on prognosis and therapy, we screened 624 gliomas from 71 young and 553 adult patients for MMR deficiency by MSI analysis using three highly sensitive diagnostic markers.
  • A malignant glioma from an adult patient displayed MSI and concomitant loss of nuclear MSH2 and MSH6 protein expression (0.16%; 1/619).
  • No evidence for MSI or loss of MMR protein expression was observed in 71 gliomas from young patients (0%; 0/71) including 41 high-grade astrocytic tumors.
  • Overall, we observed a much lower incidence of MSI among high-grade pediatric gliomas than initially reported and suggest that MMR deficiency does not play a major role in the pathogenesis of glial neoplasms.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Microsatellite Instability
  • [MeSH-minor] Adult. Child. DNA-Binding Proteins / metabolism. Humans. Immunohistochemistry. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388945.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA-Binding Proteins
  •  go-up   go-down


61. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • Hypopituitarism represents the consequence of many conditions, in both the adult and child population.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications
  • [MeSH-minor] Adult. Aged. Arginine. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Growth Hormone / blood. Growth Hormone-Releasing Hormone. Humans. Hydrocortisone / blood. Luteinizing Hormone / blood. Male. Middle Aged. Neurosurgical Procedures / adverse effects. Pituitary Function Tests. Prospective Studies. Somatomedins / analysis. Testosterone / blood. Thyrotropin / blood. Thyroxine / blood

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


62. Goldman A, Hewitt M, Collins GS, Childs M, Hain R, United Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses' Forum Palliative Care Working Group: Symptoms in children/young people with progressive malignant disease: United Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses Forum survey. Pediatrics; 2006 Jun;117(6):e1179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were significant differences between the symptoms associated with central nervous system tumors and other groups.
  • Pain other than headache occurred more commonly in children with solid tumors (98.4%) than in others (87%).
  • Neurologic symptoms, including headache, were universal among those with central nervous system tumors.
  • [MeSH-major] Neoplasms / complications. Surveys and Questionnaires
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740818.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Rousseau A, Kujas M, Bergemer-Fouquet AM, van Effenterre R, Hauw JJ: Survivin expression in ganglioglioma. J Neurooncol; 2006 Apr;77(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy.
  • These are usually well differentiated neuroepithelial tumors composed of neurons in association with neoplastic glial cells.
  • Ten lesions were low-grade neoplasms whereas 5 were high-grade tumors.
  • Two additional tumors expressed survivin upon relapse.
  • Extended lifespan in survivin expressing cells might enhance aggressive behavior in these tumors through accumulation of mutations, thereby allowing progression to malignant phenotypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ganglioglioma / metabolism. Ganglioglioma / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):173-83 [12241112.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):989-1003 [9041162.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7494-506 [15326475.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1055-9 [8847572.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2229-37 [15512811.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):360-8; discussion 368-9 [10825522.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] J Neurooncol. 2005 May;72(3):203-8 [15937641.001]
  • [Cites] Epilepsia. 1993 Jul-Aug;34(4):609-15 [8330569.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):310-4 [1476942.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2100-4 [10561264.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):59-66 [12125968.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1204-9 [11092988.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):867-73 [8246055.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):55-8 [11223561.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):557-64 [9856655.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 16292482.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


64. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG: A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
  • PURPOSE: The quality of life (QOL) and neurocognitive function of patients with brain tumors are negatively affected by the symptoms of their disease and brain radiation therapy (RT).
  • We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a central nervous system (CNS) stimulant on QOL and cognitive function in patients undergoing RT.
  • METHODS AND MATERIALS: Sixty-eight patients with primary or metastatic brain tumors were randomly assigned to receive d-MPH or placebo.
  • CONCLUSIONS: Prophylactic use of d-MPH in brain tumor patients undergoing RT did not result in an improvement in QOL.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Central Nervous System Stimulants / therapeutic use. Cognition / drug effects. Fatigue / prevention & control. Methylphenidate / therapeutic use. Quality of Life
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Double-Blind Method. Female. Humans. Least-Squares Analysis. Male. Middle Aged. Patient Dropouts / statistics & numerical data. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869448.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U10CA81851
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  •  go-up   go-down


65. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J: Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol; 2009 Dec;118(6):737-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the immunopathological analysis of the brain and tumor of two patients who died of anti-NMDAR-associated encephalitis, and of the tumor of nine patients who recovered.
  • All tumors showed NMDAR-expressing neurons and inflammatory infiltrates.
  • No complement deposits were observed in any of the central nervous system regions examined.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):230-7 [15652424.001]
  • [Cites] Brain. 1999 Jan;122 ( Pt 1):27-39 [10050892.001]
  • [Cites] J Pathol. 1993 Oct;171(2):83-98 [7506771.001]
  • [Cites] N Engl J Med. 1990 Jun 28;322(26):1844-51 [2348838.001]
  • [Cites] Acta Neuropathol. 2002 May;103(5):509-15 [11935268.001]
  • [Cites] Neurology. 2008 Feb 12;70(7):504-11 [17898324.001]
  • [Cites] Lancet Neurol. 2008 Dec;7(12):1091-8 [18851928.001]
  • [Cites] Ann Neurol. 2009 Jul;66(1):11-8 [19670433.001]
  • [Cites] Nat Clin Pract Neurol. 2007 May;3(5):291-6 [17479076.001]
  • [Cites] Ann Neurol. 2007 Jan;61(1):25-36 [17262855.001]
  • [Cites] Neurology. 2006 Jul 11;67(1):146-9 [16832096.001]
  • [Cites] Pediatr Radiol. 2005 Jul;35(7):694-7 [15723218.001]
  • (PMID = 19680671.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R56 CA089054; United States / NCI NIH HHS / CA / R01 CA089054-02; United States / NCI NIH HHS / CA / CA107192-01; United States / NCI NIH HHS / CA / R01 CA107192-01; United States / NCI NIH HHS / CA / R01CA89054; United States / NCI NIH HHS / CA / R01 CA107192; United States / NCI NIH HHS / CA / R01CA107192; United States / NCI NIH HHS / CA / CA089054-02; United States / NCI NIH HHS / CA / R01 CA089054
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Receptors, N-Methyl-D-Aspartate
  • [Other-IDs] NLM/ NIHMS174149; NLM/ PMC2888642
  •  go-up   go-down


66. Barnes M, Eberhart CG, Collins R, Tihan T: Expression of p75NTR in fetal brain and medulloblastomas: evidence of a precursor cell marker and its persistence in neoplasia. J Neurooncol; 2009 Apr;92(2):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • p75 neurotrophin receptor (p75NTR) is a member of the tumor necrosis factor superfamily, and plays a significant role in nervous system development. p75NTR has a dual (proliferative/apoptotic) role in neurogenesis and binds pro-neurotrophins with high affinity.
  • We analyzed p75NTR expression in various parts of the fetal and adult human central nervous system, and in 75 patients with medulloblastomas.
  • The staining was present in gestational weeks 20-40, while no staining was identified elsewhere in the fetal brain or within the adult cerebellum. p75NTR positive cells were also positive with the proliferation marker ki-67, but were negative for ret, reelin, CD133, CD34, and cleaved caspase 3.
  • The persistence of p75NTR in a small group of medulloblastomas raises the possibility that in such tumors, the receptor could be a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain / metabolism. Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Receptor, Nerve Growth Factor / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1994 May;11(2):85-97 [7809510.001]
  • [Cites] Curr Opin Neurobiol. 2002 Jun;12(3):260-7 [12049931.001]
  • [Cites] Curr Opin Neurobiol. 2005 Feb;15(1):49-57 [15721744.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23 (31):7951-7 [16258095.001]
  • [Cites] J Comp Neurol. 1996 Jun 10;369(4):591-618 [8761930.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545-64 [16939974.001]
  • [Cites] Prog Neurobiol. 2005 Oct;77(3):201-14 [16297524.001]
  • [Cites] Mol Cell Neurosci. 2003 Jan;22(1):1-13 [12595234.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):347-52 [9440031.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Jan;35(1):32-5 [7700480.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2409-18 [11923404.001]
  • [Cites] J Neurosci. 2000 Sep 1;20(17):6340-6 [10964939.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 May;60(5):462-9 [11379821.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11294-301 [11150291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):441-9 [15198123.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):257-82 [12175339.001]
  • [Cites] Clin Neuropathol. 1995 Mar-Apr;14(2):72-81 [7606900.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):673-81 [16423996.001]
  • [Cites] Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29 [7720210.001]
  • [Cites] Nat Rev Neurosci. 2005 Aug;6(8):603-14 [16062169.001]
  • [Cites] Acta Neuropathol. 1987;73(2):115-23 [3604579.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):13-20 [16691420.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Mar;59(3):229-40 [10744061.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • (PMID = 19066726.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


67. Akiyama M, Ginsberg HJ, Munoz D: Spinal epidural cavernous hemangioma in an HIV-positive patient. Spine J; 2009 Feb;9(2):e6-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Although soft-tissue tumors such as Kaposi's sarcoma and lymphomas have been well documented in association with HIV infection, this is the first reported case of spinal epidural cavernous hemangioma.
  • [MeSH-major] Epidural Neoplasms / complications. Epidural Neoplasms / pathology. HIV Infections / complications. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / pathology
  • [MeSH-minor] Adult. Female. Humans. Laminectomy. Magnetic Resonance Imaging


68. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL: Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res; 2010 Aug 1;16(15):4038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
  • EXPERIMENTAL DESIGN: Eligible patients in both studies were adults with solid tumor or lymphoma and performance status 0-1 for whom standard therapies were not appropriate.
  • Clinically significant central nervous system (CNS) toxicity was observed using the 1-hour infusion schedule.
  • The obatoclax maximum tolerated dose (MTD) in GX001 was 1.25 mg/m(2) due to these infusional CNS events.
  • The 3-hour i.v. infusion of obatoclax administered once weekly to patients with solid tumors was better tolerated (MTD, 20 mg/m(2)), and evidence of clinical activity was observed.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Lymphoma / drug therapy. Neoplasms / drug therapy. Pyrroles / administration & dosage
  • [MeSH-minor] Adult. Aged. Area Under Curve. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8295-301 [19088047.001]
  • [Cites] Blood. 2009 Jan 8;113(2):299-305 [18931344.001]
  • [Cites] Neoplasia. 2009 Sep;11(9):945-55 [19724688.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Chem Lab Med. 2001 Jul;39(7):596-605 [11522104.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3413-20 [18451169.001]
  • [Cites] Blood. 2007 May 15;109(10):4441-9 [17227835.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5430-8 [17332241.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]
  • [Cites] J Neurophysiol. 2008 Mar;99(3):1515-22 [18160428.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):17-22 [12559172.001]
  • (PMID = 20538761.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA051008
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrroles; 0 / obatoclax
  • [Other-IDs] NLM/ NIHMS479996; NLM/ PMC3703245
  •  go-up   go-down


69. Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, Wong T, Kirkpatrick J, Turkington T, Hollis D, Marks LB: Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1082-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A prospective study was performed to formally relate dose-dependent radiologically defined changes in normal brain induced by radiotherapy (RT) to neurocognitive dysfunction in subjects with primary brain tumors.
  • METHODS AND MATERIALS: Adult patients receiving three-dimensional RT for central nervous system (CNS) tumors were enrolled.
  • CONCLUSIONS: A dose-dependent response of CNS tissue was detected using FDG PET in this small number of patients.
  • Decreases in CNS metabolism correlated with decreased performance on neuropsychological tests for problem solving, cognitive flexibility, and global measures of psychopathology.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Cerebrovascular Circulation / radiation effects. Cognition Disorders / etiology
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Male. Middle Aged. Neuropsychological Tests. Positron-Emission Tomography. Prospective Studies. Radiopharmaceuticals / pharmacokinetics. Radiotherapy, Conformal. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755558.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Matsuda R, Nikaido Y, Yamada T, Mishima H, Tamaki R: [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia]. No Shinkei Geka; 2005 Mar;33(3):277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography demonstrated two, enhancing bilateral sided intracranial tumors.
  • The high cure rate in childhood ALL, attributable to aggressive chemotherapy and prophylatic cranial irradiation, is capable of inducing secondary brain tumor.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / prevention & control. Female. Humans. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773318.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


71. Liu HY, Zhang XL, Chen YP, Qiu SJ: [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):333-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings].
  • OBJECTIVE: To investigate the imaging features of primary central nervous system lymphoma (PCNSL).
  • RESULTS: Among the 13 patients with PCNSL, 11 were identified to have solitary tumor foci and the other 2 had multiple lesions.
  • Supratentorial tumors were found in 9 patients, infratentorial tumors in 3 patients, and both supratentorial and infratentorial tumors in 1 patient.
  • In 6 cases, the tumor presented isodensity or slight hypodensity on plain CT images, with mild or moderate enhancement after contrast agent injection.
  • Pathologically, the tumors appeared pinkish or grey-white, soft, with rich blood supply and without capsules.
  • The tumor cells were found to cluster around the blood vessels under microscope.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / pathology. Young Adult


72. Huse JT, Pasha TL, Zhang PJ: D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta Neuropathol; 2007 Jan;113(1):87-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
  • Chordomas and low-grade chondrosarcomas of the central nervous system share many histological features, generating, at times, considerable diagnostic difficulty and, not infrequently, requiring immunohistochemical analysis for appropriate classification.
  • We found that D2-40 robustly and reliably immunostains low-grade chondroid neoplasms (100% of enchondromas and 94% of grades I and II chondrosarcomas), but not chordomas.
  • Thus, we show that D2-40 behaves as a chondroid marker differentiating true chondroid neoplasms from chordoma.
  • We also demonstrate D2-40 immunoreactivity in two cases of chordoid meningioma and, in doing so, tentatively provide a means to distinguish this tumor from chordoma.
  • [MeSH-major] Antibodies, Monoclonal. Bone Neoplasms / diagnosis. Chondroma / diagnosis. Chondrosarcoma / diagnosis. Chordoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021752.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / monoclonal antibody D2-40
  •  go-up   go-down


73. Fukushima S, Terasaki M, Tajima Y, Shigemori M: Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report. J Neurosurg; 2006 Dec;105(6):912-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcomas are rare tumors that occur primarily in patients with acute myelogenous leukemia or other myeloproliferative disorders, are seldom seen in patients with acute promyelocytic leukemia (APL), and have never been reported to occur in the cerebellum.
  • Magnetic resonance images revealed an intraaxial tumor in the cerebellum.
  • Results of histopathological studies and immunohistochemical staining of the cerebellar tumor confirmed a granulocytic sarcoma.
  • Although central nervous system complications in patients with APL are rare, the data in this case highlight the need for individualized treatment when such conditions occur.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Cerebral Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Bone Marrow / pathology. Cerebellar Ataxia / etiology. Cerebellum / pathology. Chimera / genetics. Female. Gene Fusion / genetics. Granulocyte Precursor Cells / pathology. Humans. Inclusion Bodies / pathology. Karyotyping. Magnetic Resonance Imaging. Receptors, Retinoic Acid / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405265.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha
  •  go-up   go-down


74. Joseph LD, Panicker VK, Prathiba D, Damodharan J: Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient. J Assoc Physicians India; 2005 Apr;53:314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunocompromised patients are at increased risk for developing certain malignant tumors, particularly aggressive B cell lymphomas and extranodal lymphomas like primary central nervous system lymphoma and primary effusion lymphoma.
  • [MeSH-major] CD8-Positive T-Lymphocytes / pathology. HIV Infections / complications. Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / pathology. Adult. Cytoplasm / pathology. Diagnosis, Differential. Humans. Male. Risk Factors


75. Logigan C, Mihalache D, Dorneanu O, Turcu T: [Analysis of 62 cases of nosocomial staphylococcal meningitis admitted to the Iaşi Hospital of Infectious Diseases over a period of 21 years]. Rev Med Chir Soc Med Nat Iasi; 2010 Jan-Mar;114(1):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The development of nosocomial meningitis was subsequent to interventions on the central nervous system for haematoma, ventriculo-peritoneal shunts, tumors, spinal anesthesia.
  • [MeSH-minor] Adolescent. Adult. Ceftazidime / therapeutic use. Child. Child, Preschool. Colistin / therapeutic use. Drug Therapy, Combination. Female. Gentamicins / therapeutic use. Hospitals, Isolation. Humans. Infant. Male. Medical Records. Microbial Sensitivity Tests. Middle Aged. Quinolones / therapeutic use. Retrospective Studies. Romania. Staphylococcus aureus / isolation & purification. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. COLISTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509285.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins; 0 / Quinolones; 9M416Z9QNR / Ceftazidime; Z67X93HJG1 / Colistin
  •  go-up   go-down


76. Pinto F, Sacco E, Volpe A, Gardi M, Totaro A, Calarco A, Racioppi M, Gulino G, D'Addessi A, Bassi PF: [Doping and urologic tumors]. Urologia; 2010 Apr-May;77(2):92-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Doping and urologic tumors].
  • [MeSH-major] Anabolic Agents / adverse effects. Doping in Sports. Erythropoietin / adverse effects. Human Growth Hormone / adverse effects. Urologic Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Adrenergic beta-Antagonists / administration & dosage. Adrenergic beta-Antagonists / adverse effects. Adrenergic beta-Antagonists / pharmacology. Animals. Aromatase Inhibitors / administration & dosage. Aromatase Inhibitors / adverse effects. Aromatase Inhibitors / pharmacology. Cell Transformation, Neoplastic / drug effects. Central Nervous System Stimulants / administration & dosage. Central Nervous System Stimulants / adverse effects. Central Nervous System Stimulants / pharmacology. Diuretics / administration & dosage. Diuretics / adverse effects. Diuretics / pharmacology. Drug Synergism. Female. Hormones / administration & dosage. Hormones / adverse effects. Humans. Insulin-Like Growth Factor I / physiology. Male. Neoplasms, Experimental / chemically induced. Risk. Substance-Related Disorders / complications. Young Adult

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890867.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Anabolic Agents; 0 / Aromatase Inhibitors; 0 / Central Nervous System Stimulants; 0 / Diuretics; 0 / Hormones; 11096-26-7 / Erythropoietin; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


77. Chan MD, Tatter SB, Lesser G, Shaw EG: Radiation oncology in brain tumors: current approaches and clinical trials in progress. Neuroimaging Clin N Am; 2010 Aug;20(3):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation oncology in brain tumors: current approaches and clinical trials in progress.
  • Radiation therapy remains a critical therapeutic modality in the treatment of adult brain tumors.
  • However, its use continues to evolve depending on the histologic findings of the brain tumor.
  • In low-grade gliomas, the life expectancy is much greater, and the possibility of late effects of radiotherapy have shaped contemporary trials to attempt to identify groups that benefit from radiotherapy versus the ones that may defer radiotherapy until tumor progression.
  • With primary central nervous system lymphoma, the advent of high-dose methotrexate-based chemotherapy and the risk of severe early neurocognitive toxicity have brought the role of radiotherapy into question.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Lymphoma / radiotherapy. Meningioma / radiotherapy. Radiation Oncology / methods. Randomized Controlled Trials as Topic / methods
  • [MeSH-minor] Adult. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20708554.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


78. Benedetti E, Galzio R, D'Angelo B, Cerù MP, Cimini A: PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Res; 2010;2010:427401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.
  • Neuroepithelial tumors represent a heterogeneous class of human tumors including benignant and malignant tumors.
  • The incidence of central nervous system neoplasms ranges from 3.8 to 5.1 cases per 100,000 in the population.
  • Among malignant neuroepithelial tumors, with regard to PPAR ligands, the most extensively studied were tumors of astrocytic origin and neuroblastoma.
  • PPARs are expressed in developing and adult neuroepithelial cells, even if with different localization and relative abundance.
  • The majority of malignant neuroepithelial tumors have poor prognosis and do not respond to conventional therapeutic protocols, therefore, new therapeutic approaches are needed.
  • This review will focus on the major studies dealing with PPAR expression in gliomas and neuroblastoma and the therapeutic implications of using PPAR agonists for the treatment of these neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):121-38 [10725467.001]
  • [Cites] Biochim Biophys Acta. 2000 May 1;1474(3):397-409 [10779693.001]
  • [Cites] J Neurosci Res. 2000 Jul 1;61(1):67-74 [10861801.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):330-9 [10935488.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):6862-7 [10995830.001]
  • [Cites] EXS. 2000;89:141-51 [10997287.001]
  • [Cites] Int J Dev Biol. 2000 Aug;44(5):429-42 [11032176.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5558-64 [11034103.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):161-9 [11132930.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):98-104 [11205925.001]
  • [Cites] Glia. 2001 Mar 1;33(3):191-204 [11241737.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):37-41 [11464901.001]
  • [Cites] Neurochem Res. 2006 Nov;31(11):1305-16 [17053972.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1134-7 [17184491.001]
  • [Cites] Neurosci Lett. 2007 Apr 24;417(1):72-7 [17324516.001]
  • [Cites] J Cell Physiol. 2007 Jun;211(3):837-47 [17390299.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1745-54 [17541035.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1771(8):1031-45 [17569578.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):2093-106 [17662640.001]
  • [Cites] J Cell Physiol. 2008 Oct;217(1):93-102 [18446822.001]
  • [Cites] Stem Cell Rev. 2008 Dec;4(4):293-303 [18561036.001]
  • [Cites] Acta Pharmacol Sin. 2009 Jul;30(7):935-46 [19503102.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4195-202 [11564675.001]
  • [Cites] J Neurocytol. 2001 Jan;30(1):21-33 [11577243.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1747-55 [11698335.001]
  • [Cites] Bull Cancer. 2002 Jan;89(1):23-8 [11847022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2613-8 [11867749.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Int J Dev Biol. 2002 Jan;46(1):105-14 [11902671.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1052-60 [12065618.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5114-27 [12077340.001]
  • [Cites] J Neurocytol. 2001 Aug;30(8):671-83 [12118155.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] J Chem Neuroanat. 2003 Jan;25(1):29-38 [12573457.001]
  • [Cites] Curr Opin Lipidol. 2003 Apr;14(2):129-35 [12642780.001]
  • [Cites] Front Biosci. 2003 May 1;8:d577-88 [12700119.001]
  • [Cites] Brain Res. 2003 Jun 13;975(1-2):10-21 [12763589.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] J Neurochem. 2003 Nov;87(3):742-51 [14535956.001]
  • [Cites] Neuroscience. 2004;123(1):131-45 [14667448.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8976-85 [14699130.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23882-91 [15051725.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):83-91 [15171682.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):419-29 [15231248.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):493-502 [15254749.001]
  • [Cites] Oncol Res. 2004;14(7-8):345-54 [15301425.001]
  • [Cites] Biochem Soc Trans. 2004 Nov;32(Pt 5):840-2 [15494029.001]
  • [Cites] Neuroscience. 2005;130(2):325-37 [15664689.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):806-13 [15665144.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14145-53 [15695504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2340-5 [15701701.001]
  • [Cites] Neuroscience. 2005;131(3):577-87 [15730864.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18667-82 [15774422.001]
  • [Cites] Neoplasma. 2005;52(2):126-36 [15800711.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):157-68 [16009482.001]
  • [Cites] Prog Lipid Res. 2006 Mar;45(2):120-59 [16476485.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1503-12 [16820965.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1524-33 [16887936.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Sep;15(9):1039-49 [16916271.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):879-88 [16969347.001]
  • [Cites] Cell. 1992 Mar 6;68(5):879-87 [1312391.001]
  • [Cites] J Cell Physiol. 1992 Sep;152(3):536-44 [1506412.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):645-50 [2129546.001]
  • [Cites] N Engl J Med. 1985 Oct 31;313(18):1111-6 [4047115.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2643-52 [4748425.001]
  • [Cites] Science. 1984 Jun 8;224(4653):1121-4 [6719137.001]
  • [Cites] J Natl Cancer Inst. 1982 Apr;68(4):589-96 [7040765.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):354-66 [8536636.001]
  • [Cites] Cell Growth Differ. 1996 Jun;7(6):775-85 [8780891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41 [8990192.001]
  • [Cites] J Neurosci Res. 1998 Mar 1;51(5):563-73 [9512000.001]
  • [Cites] J Neurochem. 1998 Apr;70(4):1366-75 [9523552.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):2748-54 [9607781.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):465-70 [9660931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3344-52 [9699665.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):137-43 [9744270.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1049-55 [9797355.001]
  • [Cites] J Nutr. 1999 Feb;129(2S Suppl):575S-580S [10064336.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35881-8 [10585473.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):103-8 [10638762.001]
  • [Cites] J Med Chem. 2000 Feb 24;43(4):527-50 [10691680.001]
  • (PMID = 20339586.001).
  • [ISSN] 1687-4765
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2841252
  •  go-up   go-down


79. Naggara O, Brami-Zylberberg F, Rodrigo S, Raynal M, Meary E, Godon-Hardy S, Oppenheim C, Meder JF: [Imaging of intracranial metastases in adults]. J Radiol; 2006 Jun;87(6 Pt 2):792-806
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial metastases account for up to 35% of intracranial tumors in adult.
  • They can involve any part of the central nervous system: brain, meninges and cranial nerves.
  • Any systemic tumor can metastasize to the brain; the most common primaries include lung, breast and melanoma.
  • Imaging plays a major role in the evaluation and management of patients with metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778748.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


80. Ferguson SD, Musleh W, Gurbuxani S, Shafizadeh SF, Lesniak MS: Intracranial mucosa-associated lymphoid tissue (MALT) lymphoma. J Clin Neurosci; 2010 May;17(5):666-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphomas are a rare lymphoid tumor.
  • These low-grade tumors respond favorably to a combination of surgery and post-operative regional external beam radiotherapy.
  • [MeSH-major] Dura Mater / surgery. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202849.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


81. Maruya J, Narita E, Nishimaki K, Heianna J, Miyauchi T, Minakawa T: Primary cystic germinoma originating from the midbrain. J Clin Neurosci; 2009 Jun;16(6):832-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following chemotherapy and radiotherapy, the symptoms improved and the tumor disappeared.
  • We propose that primary intracranial germinoma should be included in the differential diagnosis of midbrain tumors, because early diagnosis and appropriate treatment for midbrain germinoma improves clinical outcome.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Central Nervous System Cysts / pathology. Germinoma / pathology. Mesencephalon / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Biopsy. Carboplatin / administration & dosage. Diplopia / etiology. Etoposide / administration & dosage. Humans. Male. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299138.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


82. Grieb S, Kruse R, Bruch-Gerharz D, Reifenberger J: [Tuberous sclerosis: diagnostic criteria and new treatment approaches]. Hautarzt; 2008 Oct;59(10):774-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With a prevalence of 1 in 6,000 births, tuberous sclerosis is a relatively frequent hamartoma and tumor syndrome inherited as an autosomal dominant trait, which manifests primarily on the skin and in the central nervous system.
  • Decisive factors for morbidity and mortality and thus for the prognosis are the changes in the central nervous system in the form of cortical hamartomas.
  • Various studies provided evidence that the macrolide rapamycin decreases growth of brain and kidney tumors by specific inhibition of mTOR kinase.
  • [MeSH-minor] Adult. Humans. Male. Recombinant Proteins


83. He S, Iwashita T, Buchstaller J, Molofsky AV, Thomas D, Morrison SJ: Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo. Dev Biol; 2009 Apr 15;328(2):257-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The polycomb gene Bmi-1 is required for the self-renewal of stem cells from diverse tissues, including the central nervous system (CNS).
  • Bmi-1 expression is elevated in most human gliomas, irrespective of grade, raising the question of whether Bmi-1 over-expression is sufficient to promote self-renewal or tumorigenesis by CNS stem/progenitor cells.
  • Analysis of two independent lines with expression in the fetal and adult CNS demonstrated that transgenic neural stem cells formed larger colonies, more self-renewing divisions, and more neurons in culture.
  • However, in vivo, Bmi-1 over-expression had little effect on CNS stem cell frequency, subventricular zone proliferation, olfactory bulb neurogenesis, or neurogenesis/gliogenesis during development.
  • Bmi-1 transgenic mice were born with enlarged lateral ventricles and a minority developed idiopathic hydrocephalus as adults, but none of the transgenic mice formed detectable CNS tumors, even when aged.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] Cell. 2000 Aug 18;102(4):407-10 [10966103.001]
  • [Cites] Mol Cell Neurosci. 2001 Feb;17(2):259-73 [11178865.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2409-12 [11289106.001]
  • [Cites] Gene Ther. 2001 Feb;8(4):268-73 [11313800.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1372-6 [11355949.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):77-83 [12573439.001]
  • [Cites] Cell. 1992 Dec 11;71(6):973-85 [1458542.001]
  • [Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):589-97 [1478958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6 [7690960.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3161-4 [8414519.001]
  • [Cites] Genes Dev. 1994 Apr 1;8(7):757-69 [7926765.001]
  • [Cites] Eur J Neurosci. 1997 Mar;9(3):452-62 [9104587.001]
  • [Cites] J Comp Neurol. 1997 Aug 18;385(1):95-116 [9268119.001]
  • [Cites] Annu Rev Neurosci. 1999;22:511-39 [10202547.001]
  • [Cites] Immunity. 1999 Sep;11(3):281-8 [10514006.001]
  • [Cites] Immunity. 2004 Dec;21(6):843-51 [15589172.001]
  • [Cites] Neuron. 2005 May 5;46(3):389-94 [15882637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7635-40 [15897469.001]
  • [Cites] J Neurosci. 2005 Jun 15;25(24):5774-83 [15958744.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1438-43 [15964995.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6225-32 [16778197.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2110-20 [16882984.001]
  • [Cites] Nat Methods. 2006 Oct;3(10):801-6 [16990812.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6960-6 [17145814.001]
  • [Cites] Mol Cell. 2006 Dec 8;24(5):701-11 [17157253.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):525-30 [17344414.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):238-42 [17728714.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):328-41 [17936558.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):535-41 [17917742.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):87-99 [18371338.001]
  • [Cites] Cell. 2008 Oct 17;135(2):227-39 [18957199.001]
  • [Cites] J Comp Neurol. 2003 May 26;460(2):266-79 [12687690.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):337-41 [15029199.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] J Comp Neurol. 2004 Nov 8;479(2):168-80 [15452856.001]
  • [Cites] Cell. 1991 May 31;65(5):737-52 [1904008.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15 [10571412.001]
  • (PMID = 19389366.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046592; United States / NIAMS NIH HHS / AR / AR20557; United States / NCI NIH HHS / CA / CA46592; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / P30 CA046592-23; None / None / / P30 CA046592-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Bmi1 protein, mouse; 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  • [Other-IDs] NLM/ NIHMS248858; NLM/ PMC2996717
  •  go-up   go-down


84. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • The differential diagnosis of PCNSL includes central nervous system gliomas, metastatic tumors, demyelinating disorders, subacute infarcts, and space-occupying lesions due to an infectious etiology.
  • Primary central nervous system lymphomas are treated with combined radiotherapies and chemotherapies.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


85. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL: Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One; 2010;5(3):e9544
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.
  • Herein we examined phospholipid synthesis status in brain tumors from human patients and from NPcis mice, an animal model of the human disease Neurofibromatosis Type 1 (NF1).
  • PRINCIPAL FINDINGS: In human samples, c-Fos expression was at the limit of detection in non-pathological specimens, but was abundantly expressed associated to ER membranes in tumor cells.
  • This was also observed in CNS of adult tumor-bearing NPcis mice but not in NPcis fos(-/-) KO mice.
  • A glioblastoma multiforme and a malignant PNS tumor from a NF1 patient (MPNST) showed a 2- and 4- fold c-Fos-dependent phospholipid synthesis activation, respectively.
  • CONCLUSIONS: Results highlight a role of cytoplasmic c-Fos as an activator of phospholipid synthesis in events demanding high rates of membrane biogenesis as occurs for the exacerbated growth of tumors cells.
  • They also disclose this protein as a potential target for controlling tumor growth in the nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins c-fos / biosynthesis

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] J Neurosci Res. 2009 Aug 1;87(10):2273-81 [19267420.001]
  • [Cites] Neurochem Res. 2000 Jan;25(1):153-62 [10685615.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genes Dev. 2000 Nov 1;14(21):2695-700 [11069886.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):9-13 [11162469.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] FASEB J. 2001 Mar;15(3):556-8 [11259365.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4369-78 [11390664.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):71-7 [11978395.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):19-23 [12524206.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1881-94 [14767061.001]
  • [Cites] Glia. 1989;2(4):223-30 [2527821.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):568-71 [2505081.001]
  • [Cites] J Neurochem. 1990 Dec;55(6):1855-60 [2230799.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Neuron. 1992 Jan;8(1):13-23 [1730004.001]
  • [Cites] Cell. 1992 Nov 13;71(4):577-86 [1423615.001]
  • [Cites] Nature. 1992 Dec 24-31;360(6406):741-5 [1465144.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):66-7 [7537412.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] J Neurosci Res. 1996 Jan 1;43(1):93-8 [8838579.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):10-5 [9685570.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1228-35 [10461916.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):263-9 [16473383.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3551-8 [17160021.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10631-4 [18006802.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31163-71 [18784083.001]
  • [Cites] J Neurosci Res. 2009 Mar;87(4):857-65 [18951474.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20209053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos
  • [Other-IDs] NLM/ PMC2832012
  •  go-up   go-down


86. Haroun HM, Mahfouz MS, Elhaj AM: Patterns of childhood cancer in children admitted to the institute of nuclear medicine, molecular biology and oncology (inmo), wad medani, gezira state. J Family Community Med; 2006 May;13(2):71-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They differ markedly from adult cancers in their nature, distribution and prognosis.
  • The patterns of childhood cancers in America and Europe are almost the same, with leukemia and central nervous system tumors accounting for over one-half of the new cases.
  • OBJECTIVE: The objective of this study is to determine the patterns of childhood cancers in Gezira State, Central Sudan.
  • RESULTS: The results showed a pattern of childhood lymphoma as the most common cancer (42.8%) followed by acute lymphoblastic leukemia (19.8%) and kidney tumor (12.8%).
  • CONCLUSION: Lymphoma, acute lymphoblastic leukemia and bone tumor commonly occurred in children above 5 years in contradistinction to kidney tumor and retinoblastoma which was prevalent in children less than 5 years of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pediatr (Phila). 1990 Feb;29(2):95-8 [2302907.001]
  • [Cites] Ann Trop Paediatr. 1989 Dec;9(4):261-5 [2482010.001]
  • [Cites] East Afr Med J. 2001 Jul;78(7):349-54 [11957257.001]
  • [Cites] Eur J Cancer Prev. 2004 Feb;13(1):47-51 [15075788.001]
  • [Cites] Neoplasma. 1989;36(2):233-43 [2716927.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]
  • [Cites] Ann Trop Paediatr. 2002 Jun;22(2):159-63 [12070951.001]
  • [Cites] East Afr Med J. 1995 Jan;72(1):25-9 [7781551.001]
  • [Cites] Afr J Med Med Sci. 1993 Mar;22(1):17-24 [7839877.001]
  • [Cites] West Afr J Med. 1995 Jul-Sep;14(3):174-80 [8519707.001]
  • [Cites] Am J Trop Med Hyg. 1996 Apr;54(4):343-7 [8615444.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):402-6 [11169966.001]
  • [Cites] Eur J Cancer. 1995;31A(5):771-82 [7640052.001]
  • (PMID = 23012108.001).
  • [ISSN] 1319-1683
  • [Journal-full-title] Journal of family & community medicine
  • [ISO-abbreviation] J Family Community Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3410067
  • [Keywords] NOTNLM ; Cancer / Leukemia / Lymphoma / Pattern / Prevalence
  •  go-up   go-down


87. Jarrell ST, Vortmeyer AO, Linehan WM, Oldfield EH, Lonser RR: Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg; 2006 Aug;105(2):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Patients with hereditary cancer syndromes may be at increased risk for the development of tumor-to-tumor metastases.
  • To gain insight into the biological nature of these lesions in the central nervous system (CNS), to determine their prevalence in a familial neoplasia syndrome, and to better define their management, the authors retrospectively examined a series of cases in which metastatic lesions developed within hemangioblastomas in patients with von Hippel-Lindau (VHL) disease.
  • METHODS: The study included all cases of VHL disease in which patients underwent resection of a CNS hemangioblastoma that contained a metastasis or were found at autopsy to have a metastasis to a hemangioblastoma between January 2002 and December 2005 at the National Institute of Neurological Disorders and Stroke (NINDS).
  • Metastasis to a CNS hemangioblastoma was found in six resected tumors (8% of all hemangioblastomas resected from patients with VHL disease at the NINDS during the study period) from six patients (five women, one man; mean age at surgery 42.5 years).
  • The primary site of metastatic disease was the kidney in five patients (renal cell carcinoma) and the pancreas in one (a pancreatic neuroendocrine tumor).
  • Two patients (including one who was also in the surgical group) were found at autopsy to have CNS metastases exclusively to spinal hemangioblastomas.
  • Emerging histopathological techniques may lead to recognition of an increasing number of cases of tumor-to-hemangioblastoma metastasis.
  • Management of cases involving tumor-to-hemangioblastoma metastases in VHL disease should be based on the histological characteristics of the primary tumor, extent of the primary disease, and completeness of the resection.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Carcinoma, Renal Cell / secondary. Cerebellar Neoplasms / secondary. Hemangioblastoma / diagnosis. Kidney Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Neuroendocrine Tumors / secondary. Pancreatic Neoplasms / diagnosis. Pheochromocytoma / secondary. Spinal Cord Neoplasms / secondary. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Brain / pathology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / diagnosis. Spinal Cord / pathology. Tomography, X-Ray Computed


88. Kamoshima Y, Sawamura Y: Update on current standard treatments in central nervous system germ cell tumors. Curr Opin Neurol; 2010 Dec;23(6):571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on current standard treatments in central nervous system germ cell tumors.
  • PURPOSE OF REVIEW: Various approaches have been used for the management of patients with germ cell tumors (GCTs) in the central nervous system (CNS); however, the optimal treatment of both germinoma and nongerminomatous GCTs remains unknown.
  • This review discusses current management strategies and late effects of therapy for CNS GCTs.
  • SUMMARY: The 10-year survival rate of CNS germinoma is approximately 90%.
  • Most patients with CNS GCTs are children and young adults.
  • Therefore, with the improving life prognosis of young patients, secondary neoplasms, secondary cerebral vasculopathy, neurocognitive deficits, and many other adverse effects induced by the initial treatments are problems to be solved in the next decade.
  • [MeSH-major] Antineoplastic Protocols / standards. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Humans. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885323.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


89. Niazi TN, Jensen EM, Jensen RL: WHO Grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options. J Neurooncol; 2009 Feb;91(3):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Supratentorial ependymomas and their anaplastic variants are relatively uncommon central nervous system neoplasms that afflict both adults and children.
  • Whereas the treatment algorithm in the pediatric population is well established, however, treatment in the adult population is less defined.
  • In our case series of three adult patients with supratentorial ependymomas, two patients had tumors of WHO Grade III (anaplastic variant) and one had tumor of WHO Grade II.
  • Twenty-four-month follow-up in case 1 yielded no tumor recurrence and no requirement of adjuvant chemotherapy.
  • In case 2, tumor recurred with leptomeningeal gliomatosis by 6 months.
  • Tumor did not recur during the 42-month follow-up.
  • The role of chemotherapy is still uncertain but may be necessary in younger patients who may have tumors that behave more like the pediatric ependymomas.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Ependymoma / pathology. Ependymoma / therapy. Frontal Lobe / pathology. Functional Laterality
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Magnetic Resonance Imaging / methods. Male. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Jan 15;106(2):388-95 [16342252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):585-9 [10837939.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91 [15667957.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] Radiographics. 2005 Mar-Apr;25(2):486-90 [15798065.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] Childs Nerv Syst. 2005 Mar;21(3):230-3 [15338180.001]
  • [Cites] Childs Nerv Syst. 1996 Sep;12(9):522-6 [8906366.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):59-66 [11477662.001]
  • [Cites] J Med Assoc Thai. 2004 Jul;87(7):829-33 [15521241.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):119-25 [8870014.001]
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] Surg Neurol. 1999 Jun;51(6):630-5 [10369231.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • (PMID = 18974933.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


90. Mussak E, Lin J, Prasad M: Cavernous hemangioma of the maxillary sinus with bone erosion. Ear Nose Throat J; 2007 Sep;86(9):565-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The substantial bone destruction and resultant widening of the right ostiomeatal complex made it difficult to differentiate this cavernous hemangioma from malignant epithelial tumors.
  • [MeSH-major] Bone Diseases / pathology. Hemangioma, Cavernous, Central Nervous System / complications. Maxillary Sinus / pathology. Maxillary Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970148.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM: Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol; 2008 Aug;62(3):433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the central nervous system (CNS).
  • Belinostat is a novel, potent, pan-HDAC inhibitor with antiproliferative activity on a wide variety of tumor cell lines.
  • DESIGN: Five adult rhesus monkeys received increasing doses of belinostat (10-60 mg/kg) as a 30-min IV infusion.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17960383.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Sulfonamides; F4H96P17NZ / belinostat
  •  go-up   go-down


92. Carey JP, Cooper T, Jallo GI, Carson BS, Guarnieri M: Ototoxicity of carboplatin delivered locally in a monkey brainstem. Int J Toxicol; 2005 Nov-Dec;24(6):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, local delivery to central nervous system (CNS) tumors might promote ototoxicity through drug release into cerebrospinal fluid (CSF).
  • The brainstems of adult monkeys were infused for 30 days at 0.42 mu l/h with 0.025 to 0.25 mg/kg (MTD) of carboplatin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393937.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K23 DC 00196
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 49DFR088MY / Platinum; BG3F62OND5 / Carboplatin
  •  go-up   go-down


93. Oshio K, Binder DK, Liang Y, Bollen A, Feuerstein B, Berger MS, Manley GT: Expression of the aquaporin-1 water channel in human glial tumors. Neurosurgery; 2005 Feb;56(2):375-81; discussion 375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the aquaporin-1 water channel in human glial tumors.
  • OBJECTIVE: Malignant glial tumors are associated with cerebral edema.
  • In the central nervous system, AQP1 is selectively expressed in the choroid plexus and thought to participate in cerebrospinal fluid production.
  • Prior studies have suggested that AQP1 may be up-regulated in glial tumors, potentially contributing to tumor-associated edema.
  • The objective of this study was to investigate the expression of AQP1 in a large series of human glial tumors.
  • METHODS: Thirty-six human glial tumors were obtained from the University of California, San Francisco Neurosurgery Tissue Bank.
  • CONCLUSION: The abnormal up-regulation of AQP1 in glial tumors suggests a potential pathological role for this membrane water channel and raises the possibility that selective AQP1 inhibition might offer a new therapeutic target for treatment of tumor-associated edema.
  • [MeSH-major] Aquaporin 1 / biosynthesis. Brain Neoplasms / metabolism. Glioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670385.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 146410-94-8 / Aquaporin 1
  •  go-up   go-down


94. Attard TM, Giglio P, Koppula S, Snyder C, Lynch HT: Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer; 2007 Feb 15;109(4):761-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis.
  • They are at an increased risk of brain tumors, including cerebellar medulloblastoma, when compared with the general population (Brain Tumor Polyposis-BTP Type 2).
  • Genotype-phenotype correlations between APC gene mutations and central nervous system (CNS) tumors have, thus far not been successful.
  • METHODS: The authors analyzed their established hereditary CRC Registry for brain tumors in FAP pedigrees (56 families, 213 individuals), pooled their patients with BTP and known APC mutations with those reported thus far elsewhere, and compared the resulting mutation distribution of FAP-BTP with the mutation distribution for APC mutations in the US.
  • RESULTS: Twenty-eight patients from 24 families were accrued, the most common brain tumor in BTP was medulloblastoma (60%) predominantly in females (12:5) under the age of 20 (mean age 14.7 SD 9.2).
  • Analysis of the pooled APC mutation data by Chi-square test of association shows an odds ratio of 3.7 (P < .005) for all brain tumor subtypes and 13.1 (P < .001) for medulloblastoma in patients harboring segment 2 APC mutation (codons 679-1224) compared to nonsegment 2 mutation.
  • CONCLUSIONS: In patients with FAP and identifiable APC gene mutation, CNS tumors, especially medulloblastoma which developed in most cases during childhood, are more common in females with FAP and APC gene mutation in codons 686-1217.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli Protein / genetics. Brain Neoplasms / complications. Mutation / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Codon. Female. Humans. Male. Pedigree. Registries


95. Pearce MS, Parker L, Windebank KP, Cotterill SJ, Craft AW: Cancer in adolescents and young adults aged 15-24 years: a report from the North of England young person's malignant disease registry, UK. Pediatr Blood Cancer; 2005 Oct 15;45(5):687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers in young adults were Hodgkin disease (19%), carcinomas (15%), central nervous system tumors (14%), germ cell tumors (13%), and leukemia (11%).
  • Comparing incidence for 1968-1977 with 1988-1997 there were significant increases in the incidence of bone tumors (rate ratio 1.72, 95% CI 1.10-2.68), testicular tumors (rate ratio 1.64, 95% CI 1.16-2.32), thyroid cancer (rate ratio 2.63, 95% CI 1.37-5.02), and malignant melanoma (rate ratio 2.04, 95% CI 1.36-3.08).
  • [MeSH-major] Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. England / epidemiology. Female. Humans. Incidence. Male. Registries. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086423.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):809-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
  • PURPOSE: Results of radiation therapy for primary central nervous system lymphoma (PCNSL) were poor in the 1970-1980s, with most reported 5-year survival rates being less than 10%.
  • The data were analyzed in relation to patient and tumor characteristics.
  • Multiple tumors were seen in 34%.
  • The median radiation dose to the tumor site was 50 Gy (range, 8-74 Gy).
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Rate / trends

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936564.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Al-Hussaini M, Hirschowitz L, McCluggage WG: Uterine neoplasms composed of rhabdoid cells do not exhibit loss of INI1 immunoreactivity and are not related to childhood malignant rhabdoid tumor. Int J Gynecol Pathol; 2008 Apr;27(2):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine neoplasms composed of rhabdoid cells do not exhibit loss of INI1 immunoreactivity and are not related to childhood malignant rhabdoid tumor.
  • Malignant rhabdoid tumors are rare childhood neoplasms which occur most commonly in the kidneys, soft tissue, and central nervous system.
  • Recently, it has been demonstrated that malignant rhabdoid tumors in childhood are characterized by biallelic deletion or mutation involving the SMARCB1/INI1 gene on chromosome 22.
  • Neoplasms with a similar morphology occur in adults, either in pure form or associated with a parent tumor.
  • It is controversial whether such neoplasms in adults are related to childhood malignant rhabdoid tumor or whether a rhabdoid morphology represents a nonspecific phenotype which can occur in a variety of neoplasms.
  • In this study, we stained a series of adult uterine neoplasms with a prominent component of rhabdoid cells with the Baf 47 antibody which detects INI1; we aimed to ascertain whether these are related to childhood malignant rhabdoid tumor.
  • Neoplasms included were an undifferentiated sarcoma consisting entirely of rhabdoid cells, 2 carcinosarcomas with a mesenchymal component composed entirely of rhabdoid cells, and 3 uterine tumors resembling ovarian sex cord tumor with rhabdoid cells.
  • In all cases, there was positive nuclear staining of the rhabdoid cells with Baf 47, suggesting an absence of gene deletion or mutation and that these neoplasms are not related to childhood malignant rhabdoid tumor.
  • In adults, we suggest that a diagnosis of malignant rhabdoid tumor should not be made without genetic confirmation or loss of immunohistochemical expression of Baf 47.
  • In the absence of these, an attempt should be made to classify such tumors on the basis of any associated parent neoplasm and/or immunohistochemical or ultrastructural evidence of specific differentiation.
  • We reviewed uterine neoplasms with a rhabdoid phenotype.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology. Transcription Factors / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Mutation / genetics. Phenotype. Retrospective Studies

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317218.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


98. Koch SV, Kejs AM, Engholm G, Møller H, Johansen C, Schmiegelow K: Leaving home after cancer in childhood: a measure of social independence in early adulthood. Pediatr Blood Cancer; 2006 Jul;47(1):61-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The risk for leaving home of survivors of hematological malignancies and solid tumors did not differ significantly from that of the control cohort.
  • In contrast, survivors of central nervous system (CNS) tumors had a significantly reduced risk for leaving home, which was most pronounced for men (relative risk, men: 0.66; 95% confidence interval, 0.55-0.80; women: 0.88, 95% confidence interval, 0.80-0.97).
  • CONCLUSION: Overall, the psychosocial effects of cancer in childhood or adolescence and its treatment on the survivor and family did not appear to impede social independence in early adulthood, except for survivors of CNS tumors.
  • [MeSH-major] Life Change Events. Neoplasms / rehabilitation. Residence Characteristics. Social Adjustment. Survivors
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Denmark. Female. Humans. Male. Proportional Hazards Models. Risk. Socioeconomic Factors

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16572415.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Smee RI, Williams JR: Medulloblastomas-primitive neuroectodermal tumours in the adult population. J Med Imaging Radiat Oncol; 2008 Feb;52(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastomas-primitive neuroectodermal tumours in the adult population.
  • There were two posterior fossa recurrences, with associated supratentorial and extra central nervous system disease.
  • [MeSH-major] Cerebellar Neoplasms / epidemiology. Medulloblastoma / epidemiology. Neuroectodermal Tumors, Primitive / epidemiology
  • [MeSH-minor] Adolescent. Adult. Databases, Factual / statistics & numerical data. Female. Follow-Up Studies. Humans. Intracranial Pressure. Male. Neoplasm Recurrence, Local. Neurosurgical Procedures. New South Wales / epidemiology. Radiotherapy, Adjuvant. Rare Diseases. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373831.001).
  • [ISSN] 1754-9477
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 29
  •  go-up   go-down


100. Wemmert S, Romeike BF, Ketter R, Steudel WI, Zang KD, Urbschat S: Intratumoral genetic heterogeneity in pilocytic astrocytomas revealed by CGH-analysis of microdissected tumor cells and FISH on tumor tissue sections. Int J Oncol; 2006 Feb;28(2):353-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral genetic heterogeneity in pilocytic astrocytomas revealed by CGH-analysis of microdissected tumor cells and FISH on tumor tissue sections.
  • FISH analysis revealed a significant percentage of cells with interspersed heterozygous deletions of TP53 in all tumors (14/14), ten cases showed also monosomy 17.
  • Besides gains of chromosomes 7 and 8, losses of these chromosomes were detected in the majority of tumors.
  • [MeSH-major] Astrocytoma / genetics. Central Nervous System Neoplasms / genetics. Genes, p53. Genetic Heterogeneity
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 7. Chromosomes, Human, Pair 8. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Microdissection. Monosomy. Nucleic Acid Hybridization

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391789.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement